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Chapter 1
INTRODUCTION
1.1 Host immunity
The immune system is an elaborate and dynamic regulatory and
communication network composed of many kinds of molecules, cells, tissues and
organs responsible for host resistance against infections initiated by microbial
pathogens. The immune system is subdivided into two arms, the innate and the
adaptive.
1.1.1 Innate Immunity
The innate immune system is the first line of defense against invading
microbial pathogens. Such pathogens first encounter an anatomical barrier which
includes skin and internal epithelial layers, as well as the chemicals they secrete.
Once the anatomical barrier is breached, cellular and humoral components of the
innate immune system are engaged to eliminate the foreign body. The major cell
types involved in innate immunity include: neutrophils, macrophages, eosinophils,
basophils, mast cells, natural killer cells and dendritic cells. These cells identify
pathogen-associated molecular patterns (PAMPs) through receptors on their
surface that are called pattern-recognition receptors (PRRs) (Lee et al., 2012).
PRRs are classified based on their ligand function, localization and/or
evolutionary relationships. Based on their functions, PRRs can be classified into
three families: secreted, endocytic and signaling PRRs. Secretory PRRs,
including mannan binding lectin and C reactive protein, are secreted into the
plasma and recognize bacterial cell components which enable them to activate
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the complement pathway and phagocytic cells. Mannan binding lectin is
produced in the liver and secreted into the bloodstream where it binds to
carbohydrates on the surface of pathogens and activates the lectin pathway of
the complement system (Worthley et al., 2005). The endocytic PRRs include
mannose receptor, scavenger receptor and opsonin receptor. They are
expressed at the surface of phagocytic cells, and function to mediate the
recognition, engulfment and destruction of microbes and/or microbial moieties
without intracellular signaling. Signaling PRRs, on the other hand, include Tolllike receptors (TLR), nucleotide-binding oligomerization domain (NOD)-like
receptors (NLR) and retinoic acid inducible gene I (RIG)-1-like helicases (RLH)
which are involved in cell activation in response to diverse microbial moieties.
Signaling PRRs are found on the cell surface (e.g., TLR2, TLR4, TLR5, TLR1/2,
and TLR2/6), associated with the endosomal membrane (e.g., TLR3, TLR7,
TLR8 and TLR9) or in the cytoplasm (NOD and caspase activating and
recruitment domain-containing proteins). They recognize specific microbial
ligands including bacterial lipopolysaccharide (LPS), flagellin and lipopeptides
(Jeannin et al., 2008). Upon activation, these receptors bind and activate the
adaptor molecules to trigger myeloid differentiation primary response gene (88)
product (MyD88) dependent and independent signaling pathways. This in turn
subsequently activates the transcription factor, nuclear factor kappa-light-chainenhancer of activated B cells (NF-κB) which regulates immune gene responses
and inflammation (Kawai and Akira, 2010). These together allow an immediate
response against microbial infection and contribute to the initiation of long-lasting
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adaptive immunity.
1.1.2 Adaptive Immunity
The adaptive immune system is composed of highly specialized, systemic
cells, including macrophages, dendritic cells and T and B cells and associated
processes that eliminate or prevent pathogen growth. Antigen presenting cells
(APCs, including dendritic cells, B cells, and macrophages) initially process and
present antigen. Several types of T cell subgroups can be activated by the
antigens which are processed and presented by APCs, and each type of T cell is
especially equipped to deal with each unique virulent factor associated with
bacterial and/or viral pathogens. There are two main subsets of T cells, known as
CD4+ and CD8+ T cells, that are distinguished by associated cell surface
molecules. T cells that are positive for CD4 are also known as T helper cells, and
this type of cell is considered as being the most prolific cytokine producers (Wang
et al., 2008). This subset of T cells can be further subdivided into Th1 and Th2
groups, and the cytokines they produce are known as Th1 and Th2 type
cytokines. Th1 type cytokines induce pro-inflammatory responses and activate
macrophages to induce the generation of cytotoxic T cells leading to a cell
mediated immune response. Interferon gamma (IFN-γ) and tumor necrosis factor
alpha (TNF-α) are the primary Th1 type cytokines (Vesosky et al., 2006). The
Th2-type cytokines, including interleukins 4, 5, 10, and 13, are associated with
anti-inflammatory responses and B cell activation leading to humoral immune
responses. Moreover, Th2 cytokines are capable of counteracting and/or
balancing Th1 cytokine mediated immune responses (Berger, 2000). CD8+ T
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cells, which are also called cytotoxic T cells, are involved in killing cancer cells as
well as cells infected by either virus or bacterial microbes. These cells express
CD8+ glycoprotein and recognize their target by binding to antigen associated
MHC class I molecules.
When helper T cells recognize the antigen presented on the surface of the
B cell, they become activated, which in turn activates the B cells (Parker, 1993).
Activated individual T and B cells are thus selected to undergo clonal expansion
in order to produce sufficient numbers of clones that differentiate into effector T
and B cells, thereby removing pathogens via either cell or humoral mediated
immune defenses (Braciale et al., 2012).
Cell mediated immunity is an immune response that involves the
activation of macrophages and natural killer cells, the production of antigen
specific T cells, and the release of various cytokines in response to antigen
stimulation. Cell mediated immunity is directed primarily against microbes that
survive in phagocytes and microbes that infect non-phagocytic cells. On the other
hand, for humoral or antibody mediated immunity, B cells differentiate into
plasma cells that secrete specific antibodies. In mammals there are five types of
antibodies: IgA, IgD, IgE, IgG, and IgM, each with different biological properties
and capabilities to recognize different kinds of antigens. Based on those specific
antibodies, each activated B cell can recognize a unique antigen and neutralize
specific pathogens (Janeway, 2001).
1.2

Inflammation
Inflammation is the first response of the immune system to a wound or
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infection and may then activate the innate immune cascade. It is characterized
by redness, heat, swelling, pain and dysfunction of the involved site. The host
reaction is protective as the purpose is to eliminate injurious stimuli (pathogens,
damaged cells, or irritants), as well as to clean up dead and dying cells and
initiate the healing process in the inflamed tissue site (Sadik et al., 2011).
Although inflammation plays an important role in isolating the infected area,
mobilizing effector cells, releasing molecules to the site and promoting healing,
improperly regulated inflammation may lead to tissue damage and enhanced
host disease.
1.2.1 Acute Inflammation
Inflammation may be classified into either acute or chronic in type, each
with different features. Its principal signs, as detailed above, include pain and
loss of function. It can be caused by mechanical trauma, chemical injuries or
infection, all of which induce tissue injury. The injured tissue will then trigger an
immediate, early and acute inflammatory response by releasing inflammatory
mediators to nearby blood vessels. These mediators begin to function within a
relatively short time period (minutes to hours) and induce increased blood flow
(due to blood vessel dilation) accompanied by vascular endothelial cell swelling
and retraction, both of which lead to increased vascular permeability (Ryan and
Majno, 1977). Another function of these mediators is to chemoattract neutrophils
to the infected tissue site. Circulating neutrophils first roll along the swollen
vascular endothelial cell and adhere to these cells. This process is mediated by a
family of molecules called selectins. Adjacent neutrophils adhere to each other,
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aggregate and undergo shape changes. When emigration begins, the neutrophils
actively migrate through the vessels into the damaged tissues (Armstrong et al.,
2004).
1.2.2 Chronic Inflammation
If the sequelae of acute inflammation are not resolved in a timely fashion,
but rather persist, continuing tissue necrosis and damage occurs and acute
inflammation may become more long term, or chronic. Moreover, some
pathogens tend to directly induce chronic rather than acute inflammation. Many
of the features of acute inflammation continue as the inflammation becomes
chronic inflammation (lasting days to years), including increased blood flow and
vascular permeability leading to leukocyte infiltration and tissue damage. During
the period of chronic inflammation, an induced progressive shift of immune cell
types (from neutrophils to macrophages) at the inflammation site will lead to
simultaneous destruction and healing of the inflamed tissue with accompanying
fibrosis and angiogenesis (Rieder et al., 2007). Macrophages, the primary cell
type of chronic inflammation, are derived from monocytes and reach the injury
site within 24-48 hours. These cells are activated to fulfill immunological and
secretory functions, including phagocytosis of pathogens and cellular debris,
while at the same time, releasing cytokines. The released cytokines activate
lymphocytes and other immune cells in response to pathogen stimulation
(Fujiwara and Kobayashi, 2005).
Both acute and chronic inflammation are tightly regulated by coordinated
functions of cytokines, chemokines, growth factors and several other processes.
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Chemokines provide directional cues for movements of leukocytes which release
cytokines at the inflammatory site to regulate the inflammatory process (Luster,
1998). For example, IL-33, a member of the IL-1 superfamily, signals through
ST2 and reduces corneal inflammation through upregulation of Th2 type
cytokines and anti-inflammatory cytokine production (Hazlett et al., 2010).
1.2.3 Inflammatory Cells
There are several types of cells involved in both acute and chronic
inflammatory responses. Langerhans cells are dendritic cells which are localized
at many mucosal sites. These cells play an important role in initiation of the
immune response in bacterial, viral, and parasitic infection, particularly in the eye
(Hazlett et al., 2002). In the skin, these epidermal dendritic cells also regulate
immune reactions in both sterile inflammation and infectious disease (Seiffert et
al., 2002). During infection, local Langerhans cells take up and process the
invading microbial antigens to become fully activated APCs. Activated
Langerhans cells are then capable of presenting processed antigens to T cells.
Under normal conditions, the corneal epithelium is devoid of MHC class II
positive Langerhans cells (Jager, 1992), but possesses its own bone marrow
derived cells, including cornea epithelial Langerhans cells and anterior stroma
dendritic cells, which can function as APC after antigen stimulation (Hamrah and
Dana, 2007). Moreover, in the peripheral conjunctiva, resident Langerhans cells
are present with antigen presenting capacity (Hazlett et al., 2002).
Activated Langerhans cells may trigger an inflammatory response by
releasing chemokines to chemoattract neutrophils which are the main cell type
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participating in acute inflammatory processes (Tamarozzi et al., 2011). During the
acute phase of inflammation, particularly after bacterial infection, neutrophils are
one of the first-responders among inflammatory cells to infiltrate and accumulate
at the inflammatory site. Since the lifespan of neutrophils is relative short
(approximately 10 hours), they need to be replenished quickly by more infiltrating
cells. Because the inflammatory mediators (such as histamine) released by
damaged tissues increase the vessel permeability, the aggregated neutrophils
emigrate from vessels into their target tissues down a concentration gradient of
the chemotactic factors (Kobayashi, 2006). Neutrophil chemotactic factors
include complement component (C5a), cytokines, chemokines and leukotriene
B4 (LTB4) (Elner et al., 1990). Chemotactic mediators bind to surface receptors
on neutrophils to induce calcium influx and, in turn trigger, assembly of
cytoskeletal contractile elements which initiate neutrophil migration (Cronstein et
al., 1990). As soon as migration to the target tissue is complete, neutrophils bind
to what is recognized as abnormal (e.g., bacterial and virus particles) and extend
pseudopodia to surround them. Pseudopodia then fuse to completely enclose
these structures to form a cytoplasmic phagosome which fuses with neutrophilic
granules. These granules discharge their contents which are exposed and lysed
by lysosomal enzymes. If the particles are bacteria, neutrophils kill and destroy
them by both oxidative and nonoxidative mechanisms. Important oxidative
mechanisms involve the release of hydrogen peroxide generated by the NADPH
oxidase system and hypochlorous acid generated by myeloperoxidase (Rosen,
2004). Important nonoxidative molecules include anti-microbial peptides (e.g.,
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defensins), lysozyme, neutral serine proteases, and bactericidal/permeability
increasing protein (BPI). Moreover, recent studies show that neutrophils are
capable of killing bacteria extracellularly. Upon activation, neutrophils secret
granule containing proteins and chromatins into the extracellular space and form
extracellular fibers or neutrophil extracellular traps (NETs). These fibers bind to
both Gram-positive and Gram-negative bacteria, degrading virulence factors, and
killing the bacteria (Brinkmann et al., 2004).
The primary cell type of chronic inflammation is the macrophage.
Macrophages are derived by the differentiation of monocytes and participate in
both innate and adaptive immune responses. Macrophages regulate the immune
system through initiating and directing the immune response, including
phagocytosis, antigen processing/presentation, cytokine production, generation
of reactive oxygen species and nitric oxide release. When monocytes migrate to
the injured tissue attracted by chemotactic factors, they will differentiate into
macrophages. These recruited cells as well as macrophages at the tissue site
(fixed macrophages), ingest the invading pathogen to form a phagosome which
fuses with lysosomes within the macrophage cytoplasm. The fusion product, the
phagolysosome, contains enzymes and toxic peroxides to digest and kill the
pathogen. After processing the pathogen, the macrophage will integrate the
antigen into the cell membrane and attach it to MHC class II molecules which
present the antigen to helper T cells (Unanue, 1984). The digested microbial
products, such as LPS, signal through PRRs (e.g., TLR4) or other surface
receptors to stimulate and activate the macrophages to secret both pro- and anti-
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inflammatory cytokines (Daniels et al., 2000). Unfortunately, sustained production
of pro-inflammatory cytokines released by macrophages may induce chronic
inflammation leading to increased tissue damage.
1.3

Corneal Innervation
The cornea is one of the most densely innervated tissues of the body

(Muller et al., 2003). Corneal nerves, composed primarily of sensory nerve fibers,
are found in many species, including the mouse (de Castro et al., 1998) and
human (Al-Aqaba et al., 2010; McKenna and Lwigale, 2010). In addition,
sympathetic (Marfurt and Ellis, 1993)
and parasympathetic nerves (Marfurt
et

al.,

1998),

which

respectively

originate from the superior cervical
and

ciliary

ganglia,

contribute

moderately to the innervation of the
cornea. At the periphery, nerve

Figure 1. Stromal nerves (human cornea) penetrate
through Bowman's membrane in anterior-cornea
whole mounts (a–c) and in a 30 μm-thick
perpendicular section (d). (From Marfurt et al., 2010).

bundles enter the cornea in a radial
fashion parallel to the corneal surface and then subdivide into smaller side
branches (Muller et al., 2003). These nerves are important not only for overall
corneal health, particularly, for the epithelial cells they innervate (Baker et al.,
1993), but also are essential in neuroimmunoregulation of the tissue.
1.4

Neuroimmunoregulation
Neuroimmunoregulation is the bidirectional communication between the

neuroendocrine and immune systems (Weigent and Blalock, 1987). It is required
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for immune system homeostasis and optimal host defense (Downing and Miyan,
2000). Neuropeptides, small protein-like molecules, are used by neurons to
communicate with each other, and as such, play an important role in these
processes (Scharrer, 1987). Of these peptides, two, namely substance P (SP)
and vasoactive intestinal peptide (VIP) are the main focus of ongoing studies in
the laboratory. SP is a neuropeptide secreted by nerves and inflammatory cells
and responsible for a pro-inflammatory type of response (O'Connor et al., 2004);
whereas VIP is an anti-inflammatory neuropeptide that affects the immune
response antithetically (Delgado et al., 2004).
1.5

VIP
VIP, a 28 amino acid

neuropeptide (Figure 2), is a
member

of

superfamily
secretin,

the

secretin

that

includes

growth

hormone

releasing peptide (GHRP) and
pituitary
activating

adenylate
peptide

cyclase
(PACAP)

Figure 2. VIP structure: protein and gene. A. sequence of
VIP family peptides. B. VIP gene structure (Delgado et al.,
2004).

(Smalley et al., 2009). VIP is
synthesized from a precursor molecule (prepro-VIP, 170 amino acids) which
contains peptide histidine methionine (PHM; in human tissues) or peptide
histidine isoleucine (PHI; its counterpart in other mammalian species) (Delgado
et al., 2004). After cleavage by several types of signal peptidases (Bloom et al.,
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1983; Delgado et al., 2004; Itoh et al., 1983), VIP is delivered by neurons to
immune organs and lymphoid tissues in the heart, gastrointestinal tract, lungs,
and the kidney (Henning and Sawmiller, 2001). VIP is also detected ocularly in
human aqueous humor (Koh et al., 2005), and corneal endothelium (Koh and
Waschek, 2000) and also is present in both human and mouse corneal nerves
(parasympathetic fibers) (Muller et al., 2003). VIPergic fibers have been identified
in the normal corneal
epithelium and show
more

immunostaining

after infection in the
stroma of BALB/c vs
B6 mice (Szliter et al.,
2007).
VIP functions by
binding to one of three
receptors to activate
the

following

two

pathways: one cAMPdependent
other

one

independent,
shown

in

and

the

cAMPas
Figure

are
3

(Chorny et al., 2006). Two

Figure 3. VIP signaling: cAMP dependent and independent
pathways (Chorny et al., 2006).
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VIP receptors are VIP-shared type 2 (VPAC1 and VPAC2) receptors (Jamen et
al., 2000) and a third one is a PACAP-preferring type 1 (PAC1) which shows
lower affinity for VIP (Laburthe and Couvineau, 2002). These VIP receptors are
type II, G protein coupled receptors (GPCR), which are detected in several types
of immune cells (Cocco et al., 2010), and can trigger a cascade of intracellular
events that differ depending on cell and receptor types. Both VPAC1 and VPAC2
mRNA are detected preferentially in CD4+, but also in CD8+ T cells purified from
mouse spleen; however, no signal is detected in either unstimulated or LPSstimulated B cells (Delgado et al., 1996). VPAC1 is also constitutively expressed
in resting CD4+ and CD8+ T cells purified from human peripheral blood (LaraMarquez

et

al.,

2001).

In

the

mouse,

BALB/c

mouse-derived

macrophages display significantly higher VIPR1 (VPAC1) mRNA levels when
compared with cells from B6 mice in both unstimulated and LPS-stimulated cells,
suggesting that the effects of VIP are mainly mediated via VIPR1 on
macrophages (Szliter et al., 2007).
The interaction between VIP and its receptors induces a wide variety of
biological activities. Among these, VIP displays several non-immune activities,
which include: systemic vasodilatation, bronchodilatation, smooth muscle
relaxation and neurotrophic effects (Delgado et al., 2004). VIP also accelerates
wound healing processes in mechanically-induced damage of human bronchial
epithelial cells (Guan et al., 2006), and protects cold-restraint stress-induced
gastric lesions and mast cell degranulation (Tuncel et al., 1998). Importantly, VIP
has been considered in itself to be a growth factor functioning during mouse
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embryonic development (Gressens et al., 1993; Gressens et al., 1997).
The immunological actions of VIP are primarily anti-inflammatory effects in
nature (Smalley et al., 2009). Such effects include: inhibition of pro-inflammatory
cytokine production and T cell proliferation (Ganea, 1996), inhibition of
macrophage chemotaxis and phagocytic activity (De la Fuente et al., 1996) and
inhibition of free radical production (Gonzalez-Rey et al., 2007). VIP can promote
generation of memory Th2 type T cells (Delgado et al., 2002) and can modulate T
cell function in mice, shifting a Th1 to a Th2 type cytokine response (GutierrezCanas et al., 2008). In various diseases, VIP reduces production of inflammatory
cytokines (TNF-α, IL-12, IL-6, and IL-1β) while stimulating anti-inflammatory
cytokines such as IL-10 and IL-1Ra production (Delgado and Ganea, 2008).
Most notable to the current dissertation is that previous studies from this
laboratory showed that after corneal infection with Pseudomonas aeruginosa (P.
aeruginosa), exogenous synthetic VIP treatment significantly ameliorated
disease and prevented corneal perforation by inhibiting pro-inflammatory
cytokines (IFN-γ, IL-1β, TNF-α, and MIP-2), while stimulating anti-inflammatory
cytokine (TGF-β1 and IL-10) production (Szliter et al., 2007).
1.6

Growth Factors
Growth factors are putatively involved in many biological activities such as

cell growth, proliferation, differentiation, oncogenesis, and wound healing (Turner
and Grose, 2010). Classical growth factors include: epidermal growth factor
(EGF), keratinocyte growth factor (KGF also known as fibroblast growth factor-7,
FGF-7), hepatocyte growth factor (HGF) and vascular endothelial growth factor
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(VEGF).
EGF functions through receptor dependent signaling and is well known for
its multifaceted actions in development and maintenance of tissue homoeostasis
(Lu and Kang, 2010). Amongst its functions, EGF stimulates epithelial growth and
differentiation (Cohen, 1962) and enhances wound healing (Brown et al., 1989).
EGF is also involved in the regulation of inflammation. As an example, during
infection with an enteropathogenic strain of Escherichia (E.) coli, oral
administration of EGF significantly reduced E. coli colonization (Buret et al.,
1998). EGF also accelerates corneal epithelial wound healing both in vivo and in
vitro and corneal re-epithelialization in an organ culture wound model (Lu et al.,
2001). KGF, or FGF-7, binds to FGFR2 (Rotolo et al., 2008) and is a homeostatic
factor with the potential for epithelial protection and repair after various insults
(Finch and Rubin, 2004). KGF is also considered as a cytokine which mediates
mesenchymal-epithelial interactions (Rubin et al., 1995). Regarding its role in
infection, intratracheal treatment with KGF increased clearance of P. aeruginosa
in an induced lung injury bacterial infection model (Viget et al., 2000), implying its
efficacy as an anti-bacterial agent. HGF, which binds to c-met receptor (Bottaro et
al., 1991), is a multifunctional polypeptide which regulates diverse cellular
processes, including cell survival, proliferation, migration, and differentiation (Liu,
2004). HGF has also been shown to have an anti-inflammatory effect due to its
ability to block NF-κB signal pathway transduction and E-selectin expression in
human umbilical vein endothelial cells (Gong et al., 2006). Interestingly, the
injured cornea releases IL-1 from epithelial cells to induce production of both
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HGF and KGF in keratocytes (Suzuki et al., 2003), suggesting a potential
beneficial effect of HGF and KGF in corneal wound healing. Another type of
growth factor, VEGF (VEGF-A), as a classical growth factor, can influence cell
proliferation, migration and survival (Penn et al., 2008), but it also can signal
through its receptors VEGFR1 and VEGFR2 to control vasculogenesis (Rini and
Small, 2005; Shibuya and Claesson-Welsh, 2006). In general, binding of VEGF-A
to VEGFR1 has anti-angiogenic effects by negative regulation of VEGFR2. If
levels of VEGFR2 are reduced by an antagonist (Tille et al., 2001) or in VEGFR2
knock out mouse embryos (Nicosia, 1998), reduced or lack of VEGFR2 inhibits
VEGF induced vascular angiogenic effects. It has been shown that VIP increases
VEGF (Valdehita et al., 2007) expression and secretion in human cancer cells
and nerve growth factor (NGF) expression (Hill et al., 2002) in mouse embryonic
neural tube.
1.7

TLRs
TLRs, the best characterized class of PRRs (Janeway and Medzhitov,

1998), play an important role in pathogen recognition and activation of innate
immunity, which may lead to activation of adaptive immunity (Medzhitov and
Janeway, 2000). Thirteen TLRs are present in humans and mice with the
exception that TLR10 is only present in humans and TLRs 11, 12 and 13 are only
expressed in mice (Beutler, 2004). TLRs are expressed in a variety of ocular
tissues, including cornea, and several other tissues, such as the retina. For
example, after infection with P. aeruginosa, TLR4 is expressed in the corneal
epithelium and stroma (Jiang el al., 2012) and its expression is significantly
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increased when compared to the normal, uninfected cornea (Huang et al.,
2006a).

Table 1. Toll-like receptors, ligands and adaptor molecules (Gomariz et al., 2007).

TLRs differ from each other in ligand specificities, expression patterns,
and target genes (Dowling et al., 2008). These receptors recognize highly
conserved PAMPs, including bacterial cell-surface LPS, lipoproteins, flagellin,
double-stranded RNA of viruses or the unmethylated CpG islands of bacterial
and viral DNA. In addition, TLR recognition is ligand specific, as summarized in
Table 1.
Based on their functions, TLRs can be divided into pro-inflammatory and
anti-inflammatory types. Pro-inflammatory TLRs function predominately as
homodimers, with some exceptions, as is the case for TLR1, TLR2 and TLR6.
TLRs also require co-receptors for optimal ligand sensitivity. For example TLR4
requires myeloid differentiation protein 2 (MD-2) to recognize LPS (Chaudhuri et
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al., 2005). Moreover, the delivery of LPS to MD-2 can be facilitated by CD14 and
LPS binding protein (LBP) (Kumar and Yu, 2006). Upon activation, adaptor
molecules, such as MyD88, TIRAP (also called MAL), TRIF and TRAM, are
recruited by TLR for signal amplification. TLRs can also amplify their signals by a
MyD88-independent pathway which requires TRIF, TBK1 and IRF3 to amplify
signaling (Takeda and Akira, 2004). These proteins activate downstream
molecules within the cell leading to NF-κB activation and consequently, induction
of genes that regulate the inflammatory response (Zhang and Ghosh, 2001).
TLRs also are involved in regulation of anti-inflammatory responses. In this
regard, the negative regulators of TLR signaling, including single Ig IL-1R-related
molecule (SIGIRR) and ST2, have been identified and characterized. SIGIRR
and ST2 sequester the recruitment of adaptor molecules including MyD88 and
IL-1 receptor-associated kinase (Sweet et al., 2001). They also inhibit the
formation of pro-inflammatory TLR signaling complexes and regulate proinflammatory cytokine and chemokine production (O'Neill, 2003).
TLR signaling is tightly regulated, since prolonged or excessive activation
of TLRs may lead to uncontrolled inflammation in the host (Shibolet and Podolsky,
2007). In this regard, in a recent study from this laboratory, murine beta-defensin2 (mBD2) was found to negatively regulate TLR2, TLR4 and TLR9 signaling, and
promoted the resistance response to corneal infection with P. aeruginosa (Wu et
al., 2009a). Other studies showed that numerous proteins, such as IL-1Rassociated kinase M (IRAK-M), A20 and Tollip, also negatively regulate TLR
signaling (Whitmore et al., 2007). Interestingly, in other studies, intraperitoneal
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administration of VIP (1 nM) down-regulated TLR-2 and TLR-4 expression in
colonic extracts in a model of Crohn’s disease and TLR-4 expression on the
surface of macrophages, dendritic cells and lymphocytes within the mesenteric
lymph nodes (Gomariz et al., 2005).
1.6

Overview and Significance
In the United States, microbial keratitis is the most frequent complication

for extended wear contact lens users. Its incidence among this group is 25,00030,000 cases each year, with treatment estimated at between $15 and $30
million, an extensive medical and economic impact (Khatri et al., 2002). P.
aeruginosa, a common Gram-negative bacteria associated with microbial
keratitis, accounts for approximately 70% of the culture-proven cases in contact
lens users (Schein et al., 1989).
P.

aeruginosa

is

an

opportunistic

pathogen

that

produces

lipopolysaccharide (LPS/endotoxin) and numerous other virulence factors,
including but not limited to bacterial toxins which contribute to the progression of
microbial keratitis (Hazlett, 2004). However, the prognosis of the disease also is
influenced by host immunity, the inflammatory response, and successful
treatment with antibiotics (Hazlett, 2004). Clinically, the disease progresses
rapidly and is characterized by a suppurative stromal infiltrate, inflammatory
epithelial edema, ocular pain and redness, stromal ulceration, decreased vision,
and oftentimes, corneal perforation (Hazlett, 2007).
In order to better understand disease pathogenesis, animal models of P.
aeruginosa-induced corneal infection have been established and include topical
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application of the bacteria after wounding, intrastromal inoculation, or placement
of a contaminated contact lens or suture on the cornea (Hazlett LD, 2004). Of
particular interest for the current studies is the defined inbred murine model of P.
aeruginosa-induced corneal infection. C57BL/6 (B6) mice are Th1 responsive to
P. aeruginosa infection and are classified as susceptible, since the cornea
perforates at 5-7 days post infection (p.i.) (Hazlett et al., 2000). In contrast,
BALB/c mice are Th2 responsive to P. aeruginosa infection and are classified as
resistant, since less destruction of the stroma occurs and the cornea does not
perforate at 5-7 days p.i. (Hazlett et al., 2000). Furthermore, a recent study from
this laboratory has found that VIP balances Th1/Th2 type cytokine levels, leading
to protection against corneal perforation in susceptible B6 mice (Szliter et al.,
2007).
Figure 4. Slit lamp photographs of
mouse eyes infected with P.
aeruginosa at 7 days p.i. A, B6,
susceptible strain; B, BALB/c,
resistant strain.

In this regard, the goal of the current dissertation is to test the following
hypotheses:
1. VIP modulates growth factor expression in microbial keratitis.
2. VIP regulates TLR signaling pathways in microbial keratitis.
3. VIP is not required for growth factors and their receptor expression in
the normal cornea, but critical for their regulation in the infected cornea.
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Chapter 2
VIP AND GROWTH FACTORS IN THE INFECTED CORNEA
2.1

Abstract
Purpose. VIP is an anti-inflammatory neuropeptide that down-regulates

pro-inflammatory cytokines and promotes healing in a susceptible model of P.
aeruginosa keratitis. Growth factors also play a role in corneal healing and
restoration of tissue homeostasis after wounding. However, whether VIP
treatment modulates growth factors to promote healing in the infected cornea
remains untested and is the purpose of this study. Methods. B6 mice were
injected with VIP and mRNA and protein levels, and immunostaining for EGF,
FGF, HGF, and VEGF-A were done. Exogenous treatment with a mixture of the
growth factors also was tested and levels of cytokines, defensins, and bacterial
counts were determined. Results. Real-time RT-PCR, immunostaining, and
ELISA data demonstrated that treatment with VIP enhanced levels of EGF, FGF,
and HGF during disease, and that VEGF-A, and associated angiogenic
molecules also were increased by VIP. Moreover, immunohistochemical studies
confirmed that both epithelial and stromal cells participated in growth factor
production. Most notably, treatment with a mixture of EGF, FGF, and HGF after
disease onset, prevented corneal perforation when compared with controls. This
outcome was associated with down-regulation of pro-inflammatory cytokines
such as macrophage inflammatory protein-2 (MIP-2), up-regulation of antiinflammatory cytokines such as TGF-β, and antimicrobials β-defensins 2 and 3,
as well as decreased plate counts at 1 day postinfection (p.i.) (p = 0.0001).
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Conclusions. Collectively, the data provide evidence that VIP treatment
modulates growth factors, angiogenic molecules, and defensins in the infected
cornea and that this in turn promotes healing and restoration of tissue
homeostasis.
2.2

Introduction
An opportunistic, gram-negative pathogen, P. aeruginosa is one of the

most virulent organisms associated with microbial keratitis and is often
associated with contact lens usage (Wilhelmus, 1987).

Both bacterial (e.g.,

lipopolysaccharide) and host factors released from infiltrating cells during
infection are thought to contribute to a rapidly progressing liquefactive stromal
necrosis (Iglewski et al., 1977; Kernacki et al., 2000; Moon et al., 1988; Pillar and
Hobden, 2002). Experimental murine models of the disease have been
established: Th1 responder mouse strains (e.g., B6) are susceptible (cornea
perforates), whereas Th2 responder strains (e.g., BALB/c) are resistant (cornea
heals) (Hazlett et al., 2000).
In previous studies using these murine models, we provided evidence that
an anti-inflammatory neuropeptide, VIP given exogenously, promotes resistance
against P. aeruginosa corneal infection by regulation of cytokine production and
subsequent alteration of the host inflammatory cell response (Szliter et al., 2007).
Neuropeptides, such as VIP are small protein-like molecules used by neurons to
bidirectionally communicate with the cells of the immune system (Weigent and
Blalock, 1987). In the eye, VIP can be detected in corneal nerves and the
aqueous humor in both mice and humans (Delgado et al., 2004). Others also
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have shown previously that VIP reduces pro-inflammatory cytokine production,
limits cell-mediated immunity, and inhibits macrophage and T cell proliferation
(Delgado et al., 2004); and by down-regulation of IL-6 and TNF-α, the
neuropeptide showed a protective effect in models of endotoxemia (Delgado et
al., 1999a). Despite these anti-inflammatory effects which have been reported in
diverse systems and which clearly modulate disease outcome, the role of VIP in
regulation of corneal healing, specifically, control of growth factor production, has
not been examined.
Classically, growth factors, which also may be considered as cytokines,
bind to their receptors and regulate cell growth, proliferation, migration, and
differentiation (Turner and Grose, 2010). Thus, the current studies investigated
the potential regulation by VIP of growth factors in P. aeruginosa-infected
corneas in B6 (susceptible) mice that exhibit lower levels of VIP when compared
with resistant (BALB/c) mice (Hazlett et al., 2000). Exogenous VIP treatment was
given to B6 mice to determine whether VIP modulates growth factor production
and thereby, favors resolution of disease. Data from these studies provide
evidence that VIP treatment leads to up-regulation of growth factor production in
the cornea after P. aeruginosa infection, and that both epithelial and stromal cells
are participatory. Furthermore, evidence is provided to show that treatment with a
mixture of growth factors, given topically after infection, prevents perforation of
the cornea. Mechanistically this is achieved by down-regulation of proinflammatory

cytokines,

up-regulation

of

anti-inflammatory

cytokines,

antimicrobials β-defensins 2 and 3, and decreased bacterial plate counts. The
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data suggest that VIP modulates growth factor production in the infected cornea
and that this in turn, contributes to better disease outcome.
2.3

Materials and Methods
Infection
Eight-week-old female B6 mice (The Jackson Laboratory, Bar Harbor, ME)

were anesthetized with ethyl ether and placed beneath a stereoscopic
microscope at ×40 magnification. The cornea of the left eye was wounded
(Rudner et al., 2000) and a 5-μL aliquot containing 1.0 × 106 CFU/μL of P.
aeruginosa (American Type Culture Collection, strain 19,660, Manassas, VA)
was topically delivered. Animals were treated humanely and in compliance with
the Association for Research in Vision and Ophthalmology Statement on the Use
of Animals in Ophthalmic and Vision Research.
Ocular Response to Bacterial Infection
Corneal disease was graded (Hazlett et al., 1987): 0 = clear or slight
opacity, partially or fully covering the pupil; +1 = slight opacity, fully covering the
anterior segment; +2 = dense opacity, partially or fully covering the pupil; +3 =
dense opacity, covering the entire anterior segment; and +4 = corneal perforation
or phthisis. After infection, a clinical score was recorded (days 1, 3, 5, and/or 7)
for each mouse (n = 5 per group per treatment for two experiments = 20 mice).
VIP Treatment
In vivo treatment with synthetic VIP (Bachem, Torrance, CA) has been
described previously (Szliter et al., 2007). In brief, B6 mice received daily IP
injections of VIP (5 nM in 100 μL sterile phosphate buffered saline, PBS) at 1 day
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before infection (Day = −1) through a maximum of 7 days p.i. Control mice were
injected similarly with sterile PBS (100 μL).
Real-time RT-PCR
Total RNA was isolated from an individual cornea of PBS, VIP, or growth
factor-treated mice (n = 5 per group per time per treatment for two experiments =
140 mice) using RNA-Stat 60 (TelTest, Friendswood, TX), per the manufacturer's
recommendations and quantitated spectrophotometrically (260 nM). One
microgram of total RNA was reverse transcribed using Moloney murine leukemia
virus (MMLV) reverse transcriptase. The 20-μL reaction mixture contained 200 U
of MMLV-reverse transcriptase, 10 U of RNasin, 500 ng of oligo (dT) primers, 10
mM dNTPs, 100 mM DTT, and MMLV reaction buffer (Invitrogen, Carlsbad, CA).
After, cDNA was amplified using SYBR Green Master Mix (SABiosciences,
Frederick, MD), per the manufacture's recommendation. Briefly, the 20-μL
reaction system contained 10 μL of SYBR Green PCR Master Mix, 1.0 μL of 10μM primer mix, 2 μL of cDNA (diluted 1/10), and diethyl pyrocarbonate water. All
primers were purchased from SABiosciences, except for β-actin which was
designed using PrimerQuest (Integrated DNA Technologies, Cambridge, MA)
whose forward primer is 5’-GAT TAC TGC TCT GGC TCC TAG C-3’; the reverse
primer is 5’-GAC TCA TCG TAC TCC TGC TTG C-3’. The primer sequences for
MIP-2, TNF-α, TGF-β (Szliter et al., 2007) and β-defensins-2 and 3 (Wu et al.,
2009a; Wu et al., 2009b) were provided previously.
Quantitative real-time RT-PCR reactions were performed (MyiQ single
color real-time RT-PCR detection system; Bio-Rad, Hercules, CA). Optimal

- 26 -

conditions for PCR amplification of cDNA were established using routine
methods (Heid et al., 1996). Relative mRNA levels were calculated after
normalization to β-actin.
Immunofluorescent Staining
Normal, uninfected, and infected eyes were enucleated from VIP, PBS,
and growth factor-treated B6 mice (n = 5 per group per time for two experiments
= 60 mice) at 1 and 5 days p.i. Tissue was immersed in 1X Dulbecco's PBS
(Mediatech, Inc., Herndon, VA), embedded (Tissue-Tek OCT compound; Miles,
Elkhart, IN), and frozen in liquid nitrogen. Ten-micrometer thick sections were cut,
mounted to polylysine-coated glass slides, and incubated in a moist chamber at
37°C overnight. After a 2-minute fixation in acetone, nonspecific staining was
blocked with 10 mM sodium phosphate buffer containing 2.5% bovine serum
albumin and donkey IgG (1:100) for 30 minutes at room temperature. For
immunostaining, sections were incubated for 1 hour each with goat anti-mouse
VEGF-A, EGF and/or HGF (R&D, Minneapolis, MN), goat anti-human FGF-7
(Santa Cruz Biotechnology, Santa Cruz, CA), goat anti-mouse β-defensin 2 (1:50,
Santa Cruz) or rabbit anti-mouse β-defensin 3 (1:50, Santa Cruz), followed by a
secondary Ab, Alexa Fluor 594 conjugated donkey anti-goat (1:1500, Invitrogen,
Eugene, OR) or Alexa Fluor 594 conjugated donkey anti-rabbit Ab (1:1500,
Invitrogen; both = red color). Sections were then incubated for 2 minutes with
nuclear acid stain (1:20,000, SYTOX Green; Lonza, Walkersville, MD). Controls
were similarly treated, but the primary Ab was replaced with the same host IgG.
Finally, sections were visualized and digital images captured with a confocal laser
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scanning microscope (Leica TCS SP2; Leica Microsystems, Bannockburn, IL).
ELISA
Growth factor protein levels were tested using ELISA kits (R&D). Corneas
from PBS and VIP-treated B6 mice were individually collected (n = 5 per group
per time per treatment for two experiments = 100 mice) at 1, 5, and 7 days p.i.
Corneas were homogenized in 0.5 mL of PBS with 0.1% Tween 20. All samples
were centrifuged at 13,000 rpm for 5 minutes and an aliquot of each supernatant
was assayed in duplicate for EGF, KGF/FGF-7 (FGF), HGF, and VEGF-A per the
manufacturer's instruction. ELISA also was used to test for receptor protein levels
for VEGFR1 and VEGFR2. The reported sensitivity of these assays is <0.95
pg/mL for EGF, <156.25 pg/mL for HGF, 15.62 pg/mL for KGF/FGF-7 (FGF), <3.0
pg/mL for VEGF-A, <9.8 pg/mL for VEGFR1, and <27 ng/mL for VEGFR2.
Growth Factor Treatment
Recombinant mouse EGF, KGF/FGF-7 (FGF) and HGF (all from R&D)
were dissolved in PBS to a final concentration of either 40 μg/mL (EGF and HGF)
or 20 μg/mL (FGF). After mice were infected, 5 μL of a mixture of the three
growth factors (2 μL EGF, 0.4 μL FGF, and 2 μL HGF in 0.6 μL PBS) was
delivered topically, once on the day of infection, twice at 1 day p.i. and once daily
through 4 days p.i. Concentrations for the growth factors were selected and
modified after review of the literature (Baldwin and Marshall, 2002; Forster et al.,
2008; Fredj-Reygrobellet et al., 1987). Controls received PBS similarly.
Bacterial Plate Counts
Corneas from PBS or growth factor-treated B6 mice were collected (n = 5
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per group per time for two experiments = 60 mice) at 1, 3, and 5 days p.i. and the
number

of

viable

bacteria

were

quantitated.

Individual

corneas

were

homogenized in sterile water containing 0.85% (wt/vol) NaCl containing 0.25%
BSA. Serial 10-fold dilutions of the samples were plated on Pseudomonas
isolation agar (Difco Laboratories, Sparks, MD) in triplicate and plates were
incubated overnight at 37°C and bacteria counted. Results are reported as log10
number of CFU per cornea ± SEM.
Statistics
The difference in clinical score between the two groups at each time point
was tested by the Mann-Whitney U test. An unpaired, two-tailed Student's t-test
was used to determine significance of all other data. For each test, differences
were considered significant at P < 0.05 and represented as mean ± SD. Each
experiment was performed twice for reproducibility and representative data from
a typical experiment are shown.
2.4

Results
mRNA Expression of Growth Factors
Whether VIP modulated mRNA expression patterns for selected growth

factors was first assessed. The mRNA expression patterns of EGF, FGF, HGF,
and EGF receptor (EGFR) are shown in Figures 5A, 5C, 5E, and 5G. Compared
with PBS, treatment with VIP significantly increased EGF (Fig. 5A) mRNA
expression in normal and infected cornea at 3 days p.i. (P < 0.05 and P < 0.001).
FGF mRNA expression (Fig. 5C) was not significantly different between groups at
all times tested. HGF mRNA expression (Fig. 5E) was significantly up-regulated
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by VIP in normal, uninfected, and infected corneas at 1 and 3 days p.i. (P < 0.01,
P < 0.05, and P < 0.01). EGFR was significantly increased at days 5 and 7 p.i. (P
< 0.01 for both). There were no significant differences between the two groups for
any of the growth factors at other time points tested (Figs. 5A, 5C, 5E, 5G).
ELISA
Protein expression patterns for the three growth factors were assessed
after examination of mRNA expression patterns. Protein expression for EGF, FGF,
and HGF also is shown in Figures 5B, 5D, and 5F. When compared with PBS,
VIP treatment upregulated EGF protein expression (Fig. 5B) later in disease (5
and 7 days p.i.; P < 0.01 and P < 0.01). Before infection and at 1 day p.i., levels
were higher in the PBS treated group (P < 0.001 and P < 0.001). VIP treatment
enhanced protein levels of FGF (Fig. 5D) only at 7 days p.i. (P < 0.05). For HGF
(Fig. 5F), VIP significantly increased protein expression at 1 and 5 days p.i. (P <
0.05 and P < 0.01) and remained elevated at 7 days p.i., but was not significant.
mRNA Expression of Angiogenic Molecules
Whether mRNA expression of angiogenic molecules were changed after
VIP also was assessed. For VEGF-A (Fig. 6A), treatment with VIP versus PBS
significantly increased mRNA levels only in the normal, uninfected cornea (P <
0.001); but no difference between the two groups was seen at either 1 or 5 days
p.i. For VEGFR1 (Fig. 6C), VIP increased mRNA expression in normal,
uninfected cornea (P < 0.001), did not differ between groups at 1 day, but
decreased levels at 5 (P < 0.01) days p.i. VIP increased VEGFR2 mRNA
expression (Fig. 6E) in normal, uninfected (P < 0.05) cornea but no differences
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were seen between groups at 1 or 5 days p.i.
ELISA Analysis
Protein expression patterns for angiogenic molecules were assessed after
VIP treatment and compared with controls. VIP versus PBS significantly
increased VEGF-A (Fig. 6B) protein expression in the infected cornea at 7 days
p.i. (P < 0.05). VEGFR1 (Fig. 6D) was not significantly different between groups
at all times tested. VEGFR2 protein levels (Fig. 6F) were significantly increased
(more than two-fold) by VIP versus PBS at 7 days p.i. (P < 0.001). No differences
in protein levels were detected between the two groups at the other times tested
(Figs. 6B, 6D, 6F). Consistent with these data (Figs. 6G, 6H), a photograph taken
with a slit lamp at 7 days p.i., shows greater vascularity in the peripheral cornea
of VIP- (Fig. 6H) versus PBS- (Fig. 6G) treated mice.
Immunostaining
Immunohistochemistry was used to allow us to spatially localize EGF, FGF,
HGF, and VEGF-A in the corneas of VIP- versus PBS-treated B6 mice at 1 (Figs.
7A–J) and 5 days p.i. (Figs. 8A–J). At 1 day p.i. slightly increased
immunostaining was seen for EGF after PBS versus VIP treatment (Figs. 7A, 7B,
and insets) in the epithelium and stroma. For FGF, staining was similar between
groups and in the epithelium (Figs. 7C, 7D). For HGF, VIP-enhanced stromal
immunostaining, while more epithelial staining was seen in the PBS group (Figs.
7E, 7F), VEGF-A staining was similar between groups and seen in both the
epithelium and stroma (Figs. 7G, 7H, and insets). Negative controls (primary
antibody

substituted

with

species-specific

IgG)

showed

no

positive
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immunostaining for each factor tested. An example of these negative controls
shows lack of positive immunostaining (Figs. 7I, 7J) seen with each of the factors
tested.
At 5 days p.i., EGF (Figs. 8A, 8B), FGF (Figs. 8C, 8D), HGF (Figs. 8E, 8F),
and VEGF-A (Figs. 8G, 8H) staining of increased intensity was detected in the
epithelium and stroma of VIP- versus PBS-treated mice. Negative controls
(primary antibody substituted with species-specific IgG) showed no positive
immunostaining for EGF, FGF, or VEGF-A staining at either time point tested for
either treatment. An example of these negative controls shows typical lack of
positive immunostaining seen with each of the factors tested (Figs. 8I, 8J).
Growth Factor Treatment
Because results suggested that VIP exerted some of its healing effects in
the infected cornea via modulation (enhancing) of growth factor production, the
next study was performed to test that hypothesis. To assess whether the healing
effects of VIP were through growth factor modulation, a mixture of EGF, FGF, and
HGF was topically applied after infection. Clinical score data (Figure 9A) and
photography with a slit lamp (Figs. 9B, 9C) revealed significantly less disease in
the growth factor-treated mice at 5 days p.i. (P < 0.05 for clinical score). Although
most corneas of growth factor-treated mice exhibited a +3 opacity, (only one
perforated) all corneas of PBS-treated mice had perforated at 5 days p.i. In
addition, RT-PCR analysis of growth factor- versus PBS-treated corneas showed
that mRNA levels of the pro-inflammatory cytokine, MIP-2 (Fig. 9D), were
significantly decreased (P < 0.05), while TGF-β (Fig. 9F; P < 0.001), VEGF-A (Fig.
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9G; P < 0.001), and β-defensins 2 (Fig. 9H; P < 0.05) and 3 (Fig. 9I; P < 0.001)
all were up-regulated. There was no difference between the two treatment groups
for TNF-α (Fig. 9E), or for VEGFR1 or VEGFR2 (data not shown).
Immunostaining
To begin to determine the mechanism by which growth factors given
topically contributed to corneal defense, we used immunohistochemistry to
examine infected corneas for antimicrobial molecules which had been shown by
this laboratory to be protective in the infected cornea (Wu et al., 2009a; Wu et al.,
2009b). Staining for antimicrobial β-defensins in the cornea is shown in Figures
10A–F. After growth factor versus PBS treatment, increased immunostaining for
mBD2 was detected in both the epithelium and stroma at 5 days p.i. (Figs. 10A,
10B). However, negligible staining for mBD3 was observed, with no difference
between groups (Figs. 10C, 10D). Controls (primary Ab substituted with speciesspecific IgG) showed no positive immunostaining for mBD2 or mBD3. These
negative controls showed lack of positive immunostaining and appeared similar
to staining with nuclear label (SYTOX Green; Lonza; Figs. 10E, 10F).
Bacterial Counts
To determine whether increased β-defensin production correlated with
decreased bacterial number in the cornea, bacterial plate counts (Fig. 10G) were
used to detect viable bacteria in the infected cornea of mice treated with growth
factors versus PBS at 1, 3, and 5 days p.i. When compared with controls, growth
factor treatment led to decreased bacterial plate counts at 1 (P = 0.0001), 3 (P =
0.35), and 5 days p.i. (P = 0.09), but was not significant at either of the latter
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times.
2.5

Discussion
Previously, this laboratory has provided evidence that VIP, a 28-amino

acid, anti-inflammatory neuropeptide, regulates cytokine production in P.
aeruginosa-induced keratitis, leading to decreased stromal destruction in a B6
mouse model in which the infected cornea normally perforates (Szliter et al.,
2007). In this regard, VIP is involved in the regulation of a wide variety of immune
reactions and among its numerous anti-inflammatory functions, participates in the
maintenance of immune homeostasis (Delgado et al., 2004). In addition, VIP has
been considered in itself to be a growth factor (Gressens et al., 1997), whereas
other studies have suggested that it does not function independently, but that it
may regulate other more classic growth factors such as VEGF (Valdehita et al.,
2007) and NGF (Hill et al., 2002). These growth factors can facilitate
noninfectious wound healing and may also function as anti-inflammatory
cytokines.
The present study indicates that VIP promotes production of EGF, FGF,
HGF, and VEGF-A and participates in regulating angiogenesis, all of which
contribute to resistance to P. aeruginosa keratitis. It is highly likely that these
intriguing effects may be indirect, through facilitating wound healing, and/or
epithelial barrier function, for example. It also is possible that the effect of VIP
and growth factors may modulate inflammation, balancing its required
contribution to the healing process, with its down-regulation which is permissive
to healing. In this regard, the present study has shown that both epithelial and
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stromal cells participate in growth factor production and are modulated by VIP
treatment. Unfortunately, there is a dearth of other studies concerning the role of
VIP regulating many of the classic growth factors which have been studied herein;
thus, the effects of VIP on EGF, HGF, and FGF production are initially
characterized in the present study. Despite this, previous investigators have
shown that VIP can directly activate the EGFR (Bertelsen et al., 2004) which is
confirmed at the mRNA level in the present study described herein. In addition,
we found that VIP increases EGF expression at the mRNA and protein levels and
by immunostaining at mid-to-later times p.i. However, early after infection, EGF
mRNA levels were similar between the two groups, but unexpectedly, protein and
immunostaining was slightly increased in the PBS- versus VIP-treated group
initially, suggesting that VIP has a complex regulatory function for this growth
factor. In addition, investigators reported that either EGF or VIP inhibited the
secretion of several pro-inflammatory cytokines, such as IL-1 and IL-8, and also
reduced adhesion of neutrophilic leukocytes to bronchial epithelial cells in vitro
(Zhang et al., 2006). We reported previously that VIP significantly reduced proinflammatory cytokine production in microbial keratitis, including IL-1 and MIP-2
(murine homolog of IL-8) levels (Szliter et al., 2007), but the present study shows
that this effect may have been enhanced indirectly through VIP modulation of
EGF. In fact, in another study it was reported that during infection with an
enteropathogenic strain of Escherichia coli oral administration of EGF
significantly reduced E. coli colonization (Buret et al., 1998). These findings are
consistent with a past study which has shown that VIP reduces P. aeruginosa

- 35 -

corneal bacterial load and with the present study which suggests that this effect
may have been at least in part, due to up-regulation of EGF at later times p.i. via
VIP administration.
Another growth factor, KGF/FGF-7 also participates in disease resolution
through reduction of bacterial load. In this regard, clearance of P. aeruginosa was
increased by intratracheal treatment with KGF in an induced lung injury bacterial
infection model (Viget et al., 2000). KGF also increased antimicrobials β-defensin
2 and cathelicidin (LL-37) mRNA levels which were associated with reduced
bacterial load in P. aeruginosa infection in a skin model (Erdag et al., 2004).
These data are consistent with the present study, in that VIP increased FGF
(KGF/FGF-7) expression and when used in a growth factor cocktail, applied to
the cornea after infection, increased β-defensins 2 (mRNA and protein) and 3
(mRNA). These data compliment prior work from this laboratory in which we
showed that in the cornea, both defensins are protective in a murine (BALB/c,
resistant) model of P. aeruginosa-induced microbial keratitis (Wu et al., 2009a;
Wu et al., 2009b); this inbred strain also was shown to have increased levels of
VIP when compared with B6 mice after infection (Szliter et al., 2007).
VIP also increased HGF expression at both mRNA and protein levels
(ELISA and immunostaining). This growth factor has anti-inflammatory properties
(Gong et al., 2006), in that it can target vascular endothelial cells and disrupt NFκB signaling (Giannopoulou et al., 2008), critical to regulating inflammation. We
also have reported that VIP treatment of susceptible B6 mice, decreased proinflammatory cytokines, including but not limited to IFN-γ, IL-1β, TNF-α, and MIP-
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2 and enhanced protective cytokines such as TGF-β and IL-10 (Szliter et al.,
2007). TGF-β, in addition to its regulation of immune responses, is also
profibrotic (Li et al., 2006), which may reflect increased wound healing in the VIPand/or growth factor-treated mice in which stromal destruction is diminished.
Because the present study has shown that HGF levels are enhanced after VIP
treatment in B6 mice, it is not inappropriate to suggest that the observed
protective

effects

of

VIP

could

be

affected

by

HGF

enhancement.

Immunostaining for VEGF-A was observed in both epithelium and stroma at 5
days p.i., confirming the ELISA data and providing information regarding protein
localization. High expression of VEGF-A mRNA in the newly formed epidermis
after wounding (Hong et al., 2004) is somewhat consistent with our data, which
shows a more modest effect. Elevated expression of VEGF-A may be indicative
of its exerting its growth factor functions to induce healing, cell division, migration,
cell survival, and proliferation (Rini and Small, 2005). In addition to its growth
factor properties, VEGF-A can also regulate angiogenesis (Nicosia, 1998; Tille et
al., 2001). Data from the present study show that VIP upregulates VEGFR2
protein levels more than two-fold at 5 days p.i. These data indicate that VIP, via
up-regulation of VEGFR2 has an angiogenic effect that is beneficial to the
avascular cornea for disease resolution, (confirmed by photography using a slit
lamp). The data are also consistent with the tenet that the cornea must balance
its

usually

high

threshold

for

resisting

vascular

ingrowth

(corneal

hemangiogenesis) with an ability to react to sight-threatening injuries (e.g., P.
aeruginosa), with a robust and rapid angiogenic response, required to enhance
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immune defenses (Cursiefen et al., 2006; Streilein, 2003). We hypothesize that
inflammation is reduced through the actions of VIP on pro-inflammatory cytokines
and chemokines, but also, with increased VEGF-A and R2 protein levels, as
reported herein, immune cells are better able to enter the cornea, more rapidly
participate in bacterial disposal, thus limiting bacterial-induced stromal damage;
this is followed by healing through the role of VIP in promoting anti-inflammatory
cytokines (Szliter et al., 2007), and modulating growth factor production as
shown herein. These data also are consistent with other studies using a rat
sponge model for quantitative assessment of angiogenesis which have shown
that VIP treatment improved angiogenesis in sponge sections (Hu et al., 1996).
In vitro studies have shown that exogenous application of EGF can
stimulate corneal epithelial cell migration (Nishida et al., 1992) which may have a
positive effect in microbial keratitis, contributing to restoration of epithelial barrier
function.
In addition, other studies have shown that topical application of EGF and
FGF can promote wound healing in several types of corneal wound models,
(Baldwin and Marshall, 2002; Forster et al., 2008; Fredj-Reygrobellet et al., 1987;
Nishida et al., 1992) consistent with the lack of perforation in VIP-treated mice in
which these growth factors are elevated. In this regard, topical treatment with a
growth factor cocktail containing EGF, FGF, and HGF provided evidence that at
least some of the effects seen with VIP may be evoked through these growth
factors. For example, in growth factor-treated eyes, only one of five versus all 5
corneas of PBS-treated eyes perforated; MIP-2, a chemokine that attracts
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neutrophils (PMN) into the cornea2 mRNA was reduced; while TGF-β, an antiinflammatory cytokine, was up-regulated as shown before with VIP treatment
(Szliter et al., 2007). Growth factor treatment also significantly increased βdefensins 2 and 3 mRNA expression at 5 days p.i. and β-defensin 2 staining was
enhanced at 5 days p.i. in both epithelium and stroma. These data are consistent
with a previous study showing that KGF increased β-defensin 2 expression levels
in a skin model expressing KGF/FGF-7 (Erdag et al., 2004). Most importantly,
after growth factor treatment, bacterial counts also were reduced at 1, 3, and 5
days p.i., but were significant only at 1 day p.i. These data suggest that there is a
delay in bacterial growth in the growth factor-treated cornea which may reflect
less stromal damage which could be permissive to bacterial growth.
Overall, this study provides evidence that VIP modulates growth factors,
angiogenic molecules (in both epithelium and stroma), β-defensin production,
and bacterial counts and that many of the effects observed with VIP treatment
can be compensated for through exogenous growth factor delivery.
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Figure 5. mRNA and protein expression patterns after VIP. EGF (A)
mRNA levels were significantly increased in VIP- versus PBS-treated B6 mice in
the normal, uninfected cornea and at 3 days p.i. mRNA levels of FGF (C) were
unchanged between the two groups. HGF mRNA expression levels (E) were
significantly increased by VIP in normal, uninfected cornea and at and 1 and 3
days p.i. EGFR mRNA levels (G) were increased after VIP treatment at 5 and 7
days p.i. (n = 5 per group per time per treatment for two experiments = 80 mice).
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ELISA analysis: When compared with PBS, VIP significantly increased EGF
protein expression (B) at 5 and 7 days p.i., but earlier in the normal cornea and at
1 day p.i., EGF protein levels were lower after VIP treatment. For FGF (D), VIP
increased protein levels only at 7 days p.i. For HGF (F), VIP significantly
increased protein levels at 1 and 5 days p.i. No significant changes were seen at
other times tested for all assays (n = 5 per group per time per treatment for two
experiments = 60 mice). Results for mRNA and protein data are mean ± SD.
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Figure 6. VEGF mRNA, protein, and photography with a slit lamp to
document VIP regulation. VIP versus PBS modestly elevated mRNA expression
of VEGF-A (A) only in the normal, uninfected cornea. VEGFR1 (C) mRNA levels
were increased by VIP in the normal, uninfected cornea, but levels decreased at
5 days p.i. VIP treatment increased VEGFR2 (E) in the normal cornea No
significant changes were seen at other times tested for all assays (n = 5 per
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group per time per treatment for two experiments = 40 mice). ELISA analysis: For
VEGF-A (B), VIP versus PBS increased protein levels at 7 days p.i. For VEGFR1
(D), levels were unchanged at all times tested. For VEGFR2 (F), protein levels
were increased only at 7 days p.i. Photography using a slit lamp showed that VIP
treatment decreased opacity and increased peripheral corneal vascularization
when compared with PBS (D) treatment (magnification, ×15; n = 5 per group per
time per treatment for two experiments = 40 mice). Results for mRNA and protein
data are mean ± SD. (G, H) Photographs reprinted with permission from Szliter
EA, Lighvani S, Barrett RP, Hazlett LD. Vasoactive intestinal peptide balances
pro- and anti-inflammatory cytokines in the Pseudomonas aeruginosa-infected
cornea and protects against corneal perforation. J Immunol. 2007;178:1105–1114.
Copyright 2007. The American Association of Immunologists, Inc.
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Figure 7. Immunostaining at 1 day p.i. for growth factors and VEGF-A.
EGF immunostaining was slightly increased in PBS- (A) versus VIP- (B) treated
mice (stromal as shown in the insets and epithelial). For FGF, epithelial staining
was seen and similar between groups (C, D). For HGF VIP enhanced stromal
immunostaining, while more epithelial staining was seen in the PBS group (E, F).
For VEGF-A, staining was similar between groups in both the epithelium and
stroma (G, H, and insets). An example of a negative control (primary antibody
substituted with species-specific IgG) shows lack of positive immunostaining (I, J)
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seen with each of the factors tested. Green: Sytox green nuclear label; red: Alexa
Fluor 594 secondary antibody staining; n = 5 per group per treatment for two
experiments = 20 mice).
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Figure 8. Immunostaining at 5 days p.i. for growth factor and VEGF-A. At
this time, EGF, FGF, HGF, and VEGF-A epithelial and stromal staining was more
intense in VIP- (B, D, F, H) versus PBS- (A, C, E, G) treated corneas. An
example of a negative control (primary antibody substituted with species-specific
IgG) shows lack of positive immunostaining (I, J) seen with each of the factors
tested. Green: Sytox green nuclear label; red: Alexa Fluor 594 secondary
antibody staining. Magnification, ×100; n = 5 per group per treatment for two
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experiments = 20 mice.
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Figure 9. Topical growth factor treatment and assessing disease response
by clinical evaluation and RT-PCR. Clinical scores (A) indicated statistically
significant differences at 5 (P < 0.05) days p.i. between groups. Photographs
taken with a slit lamp at 5 days p.i. showed a worsened disease response
(perforation) when comparing control (B) versus growth factor (C) treatment.
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Magnification, ×6 (n = 5 per group per treatment for two experiments = 20 mice).
mRNA levels (D–I) showed a significant decrease in MIP-2 (D), no change in
TNF-α (E), and increased TGF-β (F), VEGF-A (G), and β-defensins 2 (H) and 3 (I)
in growth factor versus control treated eyes (n = 5 per group per treatment for
two experiments = 20 mice). Results are shown as mean ± SD.
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Figure 10. Immunostaining and bacterial counts after topical growth factor
treatment. At 5 days p.i., β-defensin 2 epithelial and stromal staining was more
intense in growth factor- (B and inset) versus PBS- (A) treated corneas. At this
time, negligible staining for β-defensin 3 was seen after either growth factor (D)

- 50 -

or PBS (C) treatment. Controls, in which the primary Ab was replaced by IgG,
were negative for immunostaining (E, F) for both defensins. Green: Sytox green
nuclear label; red: Alexa Fluor 594 secondary antibody staining (n = 5 per group
per treatment for two experiments = 20 mice). (G) Bacterial counts: Growth factor
(grey filled bar) versus PBS (unfilled bar) treatment reduced bacterial plate
counts at 1, 3, and 5 days p.i., but were significant only at 1 day p.i. (n = 5 per
group per treatment for two experiments = 60 mice). Results are shown as mean
± SD.
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Chapter 3
VASOACTIVE INTESTINAL PEPTIDE DOWNREGULATES
PROINFLAMMATORY TLRS WHILE UPREGULATING ANTI-INFLAMMATORY
TLRS IN THE INFECTED CORNEA
3.1

Abstract
TLRs recognize microbial pathogens and trigger an immune response, but

their regulation by neuropeptides, such as VIP, during P. aeruginosa corneal
infection remains unexplored. Therefore, B6 mice were injected i.p. with VIP, and
mRNA, protein, and immunostaining assays were performed. After VIP treatment,
PCR array and real-time RT-PCR demonstrated that pro-inflammatory TLRs
(Chuk, IRAK1, TLR1, TLR4, TLR6, TLR8, TLR9, and TRAF6) were downregulated, whereas anti-inflammatory TLRs (SIGIRR and ST2) were up-regulated.
ELISA showed that VIP modestly down-regulated phosphorylated IKKα but upregulated ST2 ~2-fold. SIGIRR was also up-regulated, whereas TLR4
immunostaining was reduced in cornea; all confirmed the mRNA data. To
determine whether VIP effects were cAMP dependent, mice were injected with
small interfering RNA for type 7 adenylate cyclase (AC7), with or without VIP
treatment. After silencing AC7, changes in mRNA levels of TLR1, TRAF6, and
ST2 were seen and unchanged with addition of VIP, indicating that their
regulation was cAMP dependent. In contrast, changes were seen in mRNA levels
of Chuk, IRAK1, 2, TLR4, 9 and SIGIRR following AC7 silencing alone; these
were modified by VIP addition, indicating their cAMP independence. In vitro
studies assessed the effects of VIP on TLR regulation in macrophages and
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Langerhans cells. VIP down-regulated mRNA expression of pro-inflammatory
TLRs while up-regulating anti-inflammatory TLRs in both cell types. Collectively,
the data provide evidence that VIP down-regulates pro-inflammatory TLRs and
up-regulates anti-inflammatory TLRs and that this regulation is both cAMP
dependent and independent and involves immune cell types found in the infected
cornea.
3.2

Introduction
Keratitis induced by P. aeruginosa progresses rapidly and is characterized

by a suppurative stromal infiltrate with a marked mucopurulent exudate. Other
untoward characteristics include inflammatory epithelial edema, ocular pain and
redness, stromal ulceration, and often, decreased vision (Hazlett, 2004).
Experimentally, infection with P. aeruginosa leads to corneal perforation in strains
of mice, such as C57BL/6 (B6; susceptible), whereas less severe disease is seen
in similarly challenged BALB/c (resistant) animals (Hazlett et al., 2000). In
contrast, treatment of B6 mice with VIP promotes better disease outcome
postinfection with P. aeruginosa, mainly through regulation of cytokine production
and subsequent alteration of the host inflammatory cell response (Szliter et al.,
2007). Recent studies from this laboratory provided further information regarding
the anti-inflammatory effects of VIP and showed that it modulates keratitis
through regulation of growth factors, angiogenic molecules, and β defensins in
the infected cornea, contributing to healing (Jiang et al., 2011). However, the role
of VIP in the regulation of TLRs has not been well-defined, despite the fact that
other studies demonstrated that TLRs play an important role in ocular immune
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defense (Yu and Hazlett, 2006). They direct the ocular immune response by
differentially

regulating

a

variety

of

events,

including

bacterial

killing,

polymorphonuclear leukocyte infiltration, and cytokine expression at both mRNA
and protein levels (Huang et al., 2005; Huang et al., 2007; Huang et al., 2006a;
Huang et al., 2006b). In particular, TLR4, a specific receptor for LPS contained in
the outer membrane of various Gram-negative bacteria, is required for host
resistance against P. aeruginosa in the infected cornea (Huang et al., 2006a). In
fact, upon activation by P. aeruginosa, both TLR4 and TLR5 on corneal
macrophages were shown to regulate P. aeruginosa keratitis through MyD88dependent and -independent pathways (Sun et al., 2010). Therefore, it is
important to understand which TLRs are regulated by VIP, as well as the
mechanisms involved during microbial keratitis. In this regard, studies suggested
that VIP can signal through cAMP-dependent or -independent pathways (Chorny
et al., 2006), but it is not known whether this is important in VIP regulation of
TLRs in other diseases (Gomariz et al., 2007) or bacterial keratitis.
Thus, the current studies investigated the expression of TLR-signaling
pathways in P. aeruginosa-infected corneas, with or without VIP treatment, to
determine whether it regulates their expression to favor disease resolution. Our
data provide evidence that VIP treatment down-regulates pro-inflammatory TLRs
while up-regulating anti-inflammatory TLRs at both the mRNA and protein levels
in the cornea after P. aeruginosa infection and that, mechanistically, two
transduction pathways, cAMP dependent and independent, are involved.
Furthermore, in vitro studies suggest that at least two cell types in the cornea
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may be responsive, because VIP reduced pro-inflammatory TLRs and increased
anti-inflammatory TLRs in both LPS-stimulated elicited peritoneal macrophages
and XS52 (Langerhans) cells.
3.3

Materials and Methods
Infection
Eight-week-old female B6 mice were purchased from The Jackson

Laboratory (Bar Harbor, ME). Mice were anesthetized with ethyl ether and placed
beneath a stereoscopic microscope at ×40 magnification. The cornea of the left
eye was wounded (Rudner et al., 2000), and a 5 μl-aliquot containing 1.0 × 106
CFU P. aeruginosa (strain 19660; American Type Culture Collection, Manassas,
VA) was topically delivered. Animals were treated humanely and in compliance
with the Association for Research in Vision and Ophthalmology Statement on the
Use of Animals in Ophthalmic and Vision Research.
VIP treatment
Treatment with synthetic VIP was described previously (Szliter et al., 2007)
at a dosage reported to be efficacious in a lethal endotoxemia model (Delgado et
al., 1999b). In brief, using that dosage, B6 mice received daily i.p. injections of
VIP (5 nM in 100 μl sterile PBS) at 1 d before infection (day −1) through a
maximum of 7 d postinfection (p.i.). Control mice were injected similarly with
sterile PBS (100 μl).
RNA interference
Use of small interfering RNA (siRNA) was described in previous work from
this laboratory (Wu et al., 2009a). For the current studies, siRNA for type 7
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adenylate cyclase (AC7) or an appropriate scrambled control (Santa Cruz
Biotechnology, Santa Cruz, CA) was injected subconjunctivally (5 μl/mouse at a
concentration of 8 μM) into the left eye of B6 mice (n = 5/group/time) 1 d before
infection, with or without VIP treatment (described above). AC7 (4 μM) was
applied topically to the infected corneas (5 μl/mouse/time) once on the day of
infection and twice on days 1 and 3 p.i. Corneas from scrambled control, silenced
AC7, or silenced AC7 plus VIP-treated (n = 5/group/time) mice were individually
collected at 5 d p.i. and processed for RT-PCR (described below). Using a similar
assay, the efficacy of silencing AC7 in cornea (n = 5/group/time) was confirmed
by real-time RT-PCR (5 d p.i.).
Real-time RT-PCR
Total RNA was isolated from individual corneas (n = 5/group/time) or cells
using RNA-Stat 60 (Invitrogen, Carlsbad, CA), per the manufacturer’s
recommendations, and quantitated spectrophotometrically (260 nm). One
microgram of total RNA was reverse transcribed using MMLV reverse
transcriptase. The 20-μl reaction mixture contained 200 U MMLV-reverse
transcriptase, 10 U RNasin, 500 ng oligodeoxythymidine primers, 10 mM
deoxyribonucleotide triphosphate, 100 mM DTT, and MMLV reaction buffer
(Invitrogen). cDNA was amplified using SYBR Green Master Mix (SABiosciences,
Frederick, MD), per the manufacturer’s recommendation. Briefly, the reaction
system contained 10 μl SYBR Green PCR Master Mix, 0.5 μM primers, and 2 μl
cDNA (diluted 1/10) in diethyl pyrocarbonate water. All primer sets for the PCR
array were purchased as a 96-well plate (RT2 Profiler TLR Signaling Pathway
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PCR Array; SABiosciences). The individual primer sets were designed using
PrimerQuest (Integrated DNA Technologies, Cambridge, MA). Sequences of
primers for β-actin, AC7, conserved helix-loop-helix ubiquitous kinase inhibitor of
NF-κB kinase subunit α (Chuk), IRAK1, IRAK2, TLR1, TLR4, TLR6, TLR8, TLR9,
TNFR-associated factor (TRAF)6, SIGIRR, and ST2 are shown (Table 2).
ELISA
Protein levels of TLR-associated molecules were tested by ELISA.
Corneas from PBS- and VIP-treated B6 mice were individually collected (n =
5/group/time) from normal uninfected and infected mice at 1 and 7 d p.i. For total
Chuk (IKKα) and p-IKKα (Cell Signaling Technology, Danvers, MA), corneas were
homogenized in 0.5 ml lysis buffer (Cell Signaling Technology) with 1 mM PMSF
(Sigma, St. Louis, MO) and protease inhibitor (1 tablet/10 ml; Roche, Indianapolis,
IN). For ST2 (R&D Systems, Minneapolis, MN), corneas were homogenized in
0.5 ml PBS with 0.1% Tween 20 and protease inhibitor (as above). All samples
were centrifuged at 13,000 rpm for 5 min, and an aliquot of each supernatant
was assayed in duplicate for total IKKα, p-IKKα, and ST2, per the manufacturer’s
instructions.
Western blot
Corneas (n = 5/group/time) were collected from PBS- and VIP-treated
normal uninfected and infected B6 mice at 1 and 5 d p.i. Pooled corneas (n =
5/group) were lysed in 250 μl radio immunoprecipitation assay lysis buffer (Santa
Cruz Biotechnology) and homogenized for 15 min. Tissue debris was pelleted by
centrifugation for 10 min at 12,000 rpm, and protein concentration of the
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supernatant was determined by bicinchoninic acid (Bio-Rad) protein assay.
Supernatants were separated on 10% SDS-PAGE, after loading an 80-μg sample
in each lane; as a control, recombinant murine SIGIRR (15 ng; R&D Systems)
was similarly loaded. The electrophoretically separated material was transferred
to a supported nitrocellulose membrane (Bio-Rad) and blocked in a 5% solution
of nonfat dry milk prepared in 1× PBS and 0.05% Tween 20. Blots were
incubated with primary goat anti-mouse SIGIRR Ab (R&D Systems) diluted in
PBS overnight (4°C), washed three times for 10 min each with TBST, detected
with HRP-conjugated secondary Ab (R&D Systems) diluted 1/1000 in PBS
containing 5% nonfat milk, and developed using the ECL method (PerkinElmer,
Waltham, MA), per the manufacturer’s protocol. The blot was scanned on a
FluorChem E imaging system (Cell Biosciences, Santa Clara, CA), and band
relative integrated density value was analyzed by AlphaView software (Cell
Biosciences).
Immunofluorescent staining
Normal, uninfected and infected eyes were enucleated from VIP- or PBStreated B6 mice (n = 5/group/time) at 1 and 5 d p.i. Tissue was immersed in 1×
Dulbecco’s PBS (Mediatech, Herndon, VA), embedded in Tissue-Tek OCT
compound (Miles, Elkhart, IN), and frozen in liquid nitrogen. Ten-micrometer-thick
sections were cut, mounted on polylysine-coated glass slides, and incubated in a
moist chamber at 37°C overnight. After a 2-min acetone fixation, nonspecific
staining was blocked with 10 mM sodium phosphate buffer containing 2.5% BSA
and donkey IgG (1:100) for 30 min at room temperature. For immunostaining,
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sections were incubated for 1 h each with goat anti-mouse TLR4 (Santa Cruz
Biotechnology), followed by an Alexa Fluor 594-conjugated donkey anti-goat
secondary Ab (1:1500, Invitrogen). Sections were incubated for 2 min with
SYTOX Green nuclear acid stain (1:20,000; Lonza, Walkersville, MD). Controls
were treated similarly, but the primary Ab was replaced with the same host IgG.
Finally, sections were visualized (TLR4+ staining = red), and digital images were
captured with a Leica TCS SP2 confocal laser-scanning microscope (Leica
Microsystems, Bannockburn, IL).
Cell isolation, culture, and treatment
Peritoneal macrophages were elicited and isolated from B6 mice, as
described before (Szliter et al., 2007). Briefly, cells were induced into the
peritoneal cavity by i.p. injection of 1.0 ml 3% Brewer’s thioglycollate medium
(Becton Dickinson, Sparks, MD) 5 d before harvest (n = 12 mice). Cells were
collected by peritoneal lavage with DMEM and stained with trypan blue (1:1);
viable cells (>95%) were counted using a hemacytometer. After a differential cell
count, cells were collected and pooled, and 3 × 106 macrophages/well (five
wells/treatment) were seeded into six-well plates. Nonadherent cells were
removed 24 h later, and isolated macrophages were used for the in vitrostimulation assays described below. Mouse XS52 (Langerhans) cells were
cultured in complete RPMI 1640 with 10% FCS (both from Life Technologies,
Grand Island, NY) supplemented with 0.5 ng/ml murine rGM-CSF (Life
Technologies), as described previously (Huang et al., 2005). These cells (capable
of presenting protein Ag to primed CD4+ T cells) were derived from newborn
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BALB/c mouse epidermis as stable long-term cell lines (dendritic shaped,
CD45+/E-cadherin+ and B7-1-) (Xu et al., 1995). After differential cell count, 3 ×
106 XS52 (Langerhans) cells/well (five wells/treatment) were seeded into six-well
plates. Both cell types were treated with 1 μg ultrapure LPS (Escherichia coli
01111:B4 strain; which only activates the TLR4 pathway; InvivoGen, San Diego,
CA), with or without VIP (10−9 M). For both macrophage and XS52 (Langerhans)
cell experiments, which were repeated similarly once (n = 2 experiments for each
cell type), cells from each well were collected, mRNA was extracted and assayed
in duplicate by real-time RT-PCR (described above), and the data were analyzed
statistically.
Langerhans cell staining and quantitation
Normal, uninfected corneas were harvested at 1 and 3 d p.i. and placed in
0.02 mol/l EDTA (pH 7.2) for 1 h at 37°C for epithelial removal and Langerhans
cell staining. Epithelial sheets were fixed in cacodylate-buffered formaldehyde for
20 min at 4°C, washed four times with cold 0.1 mol/l cacodylate buffer, and
incubated in ADPase substrate solution containing ADPase buffer, 2% lead
nitrate, and ADP (5 mg/ml; Sigma) for 15 min at 37°C. Sheets were washed four
times with trismaleate buffer (pH 7.2), developed for 5 min in a 1:10 ammonium
sulfide solution, washed three times with buffer, mounted onto slides with glycerol,
flattened, and coverslipped (Hazlett et al., 2002). Epithelial sheets were observed
and photographed with a Zeiss Axiophot microscope with Axiocam digital
imagery (Carl Zeiss; Morgan Instruments, Cincinnati, OH) at ×375, and the
number of cells was quantitated/field (n = 12; field size = 270 μm2) by two
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investigators who were blinded to the treatment. Staining of Langerhans cells for
ADPase activity was done previously and was shown to provide data similar to
immunostaining these cells with surface markers, such as DEC205 (Hazlett et al.,
2002).
Statistics
Two-way ANOVA, followed by the Bonferroni posttest, was used for
analysis of the data shown in Figs. 11, 12, and 17 (Prism 3.0; GraphPad
Software, La Jolla, CA). One-way ANOVA, followed by the Tukey posttest, was
used for the data shown in Figs. 14–16 (SPSS, Chicago, IL). For each test,
differences were considered significant at p < 0.05, and data shown are mean ±
SEM. Each experiment was performed at least twice, and combined data are
shown, with the exception of Figs. 15 and 16, in which representative data from a
single similar experiment are provided. Infection of mice, confocal microscopy,
and Langerhans cell quantitative studies were done in a blinded fashion.
3.4

Results
PCR array and real-time RT-PCR
To determine the effects of VIP treatment on the regulation of TLRs in

cornea during bacterial keratitis, mRNA levels were tested by RT-PCR (Table 2)
and 84 TLR-related genes were profiled by PCR array at 3 d p.i. VIP treatment
decreased the expression (>3-fold) of 21 genes compared with PBS-treated
controls (Table 3). RT-PCR was used to confirm the array data and to test TLR4
(Huang et al., 2006a) and IRAK1 (Deng et al., 2006; Hacker et al., 2011), which
are important in Pseudomonas-induced infections, but were not changed on the
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PCR array greater >3-fold (TLR4, −1.11 and IRAK1, −2.9). Negative regulators of
TLRs (ST2 and SIGIRR), not included on the PCR array, that were shown
previously to promote resistance to P. aeruginosa keratitis (Huang et al., 2007;
Huang et al., 2006b) were also tested.
VIP significantly down-regulated mRNA expression for TLR1 only at 7 d p.i.
(Fig. 11A, p < 0.01). However, compared with PBS treatment, VIP decreased
mRNA levels of TLR4 only at 1 d postinfection (Fig. 11B, p < 0.001). VIP also
down-regulated mRNA levels of TLR6 at 5 and 7 d p.i. (Fig. 11C, p < 0.05 and p
< 0.001, respectively), for TLR8 only at 7 d p.i. (Fig. 11D, p < 0.001), and for
TLR9 only at 5 d p.i. (Fig. 11E, p < 0.001). Compared with PBS treatment, VIP
treatment also decreased mRNA expression of TLR adaptor molecule IRAK1 at 1
and 5 d p.i. (Fig. 11F, p < 0.001 and p < 0.001, respectively), but no differences
were seen between the groups for IRAK2 (Fig. 11G). TRAF6, which interacts with
IRAK1 (Cao et al., 1996), also was reduced at the mRNA level by VIP treatment
compared with PBS treatment at 5 and 7 d p.i. (Fig. 11H, p < 0.05 and p < 0.001,
respectively). mRNA levels of Chuk, a downstream molecule of the IRAK–
TRAF6-signaling pathway, which regulates NF-κB expression (Cao et al., 1996),
also was down-regulated by VIP at 1 and 7 d p.i. (Fig. 11I, p < 0.01 and p < 0.001,
respectively). In contrast, VIP treatment increased SIGIRR mRNA levels at 5 and
7 d p.i. (Fig. 11J, p < 0.001 for both). However, levels in both groups decreased
at 1 d p.i. ST2 mRNA levels also were increased by VIP treatment at all times
tested, but it was significant only at 7 d p.i. (Fig. 11K, p < 0.05).
ELISA and Western blot
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ELISA and/or Western blot was used to selectively confirm the mRNA data
for total IKKα (Chuk), p-IKKα, ST2, and SIGIRR. For total IKKα (Fig. 12A), there
was no significant difference between PBS and VIP treatment at any time tested.
However, compared with PBS treatment, VIP treatment slightly down-regulated
p-IKKα protein expression only at 7 d p.i. (Fig. 12B, p < 0.05). In contrast, protein
levels of ST2 (Fig. 12C) were significantly enhanced by VIP treatment compared
with PBS treatment at 7 d p.i. (p < 0.001), not different at 1 d p.i., and not
detectable in either normal sample. SIGIRR protein (Fig. 12D, 12E) was
constitutively expressed at similar levels in normal PBS- and VIP-treated mouse
cornea. At 1 d p.i., greater levels of SIGIRR (p < 0.001) were observed after VIP
treatment, with no difference between the two groups at 5 d p.i.
TLR4 immunostaining
Immunohistochemistry was used to spatially localize TLR4 (red staining) in
the cornea of VIP- versus PBS-treated B6 mice at 1 and 5 d p.i. At 1 d p.i.,
reduced TLR4 staining was seen after VIP treatment (Fig. 13B), compared with
PBS treatment (Fig. 13A), in corneal epithelium and stroma. At 5 d p.i., compared
with PBS treatment, VIP treatment further reduced TLR4 epithelial and stromal
staining (compare Fig. 13D with 13C). Controls in which primary Ab was
substituted with species-specific IgG were negative after PBS (Fig. 13E) or VIP
(Fig. 13F) treatment at 1 or 5 d p.i. (data not shown).
Silencing AC7
To determine whether the anti-inflammatory effect of VIP on TLRs was
cAMP dependent, siRNA was used in vivo to knock down AC7; it was selected
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because, among the 10 mammalian adenyl cyclase isotypes, AC7 is highly
expressed in the immune system (Duan et al., 2010). When tested at 5 d p.i., RTPCR confirmed that silencing AC7 versus scrambled control treatment
significantly decreased AC7 mRNA levels (Fig. 14A, p < 0.01) and that silencing
plus VIP treatment did not reverse the effect. Furthermore, at this time, silencing
AC7 increased mRNA levels of TLR1 (Fig. 14B), whereas TRAF6 (Fig. 14C) and
ST2 (Fig. 14D) were decreased (p < 0.05, p = 0.001, and p < 0.01, respectively).
Silencing plus VIP injection did not change the effect, indicating that VIP
regulation of these TLRs is cAMP dependent. mRNA levels of pro-inflammatory
TLRs, including Chuk (Fig. 14E), IRAK1 (Fig. 14F), TLR4 (Fig. 14G), TLR9 (Fig.
14H), and IRAK2 (Fig. 14I), were increased after silencing compared with
scrambled control treatment (p < 0.01, p < 0.01, p = 0.001, p = 0.01, and p < 0.05,
respectively); levels of the anti-inflammatory TLR SIGIRR were decreased (Fig.
14J, p = 0.001). Silencing plus VIP injection changed the effect (Chuk: p < 0.001;
IRAK1: p < 0.05; TLR4: p = 0.001; TLR9: p < 0.01; IRAK2: p < 0.05; SIGIRR: p <
0.05), indicating that VIP regulation of these molecules is cAMP independent. No
significant changes in mRNA levels of TLR6 (Fig. 14K) were seen with AC7
siRNA treatment, but VIP plus silencing decreased mRNA levels of TLR6 (p <
0.05), suggesting the possibility of its regulation by another adenyl cyclase
isoform (Song et al., 2007). No effects were seen for TLR8 (Fig. 14L), suggesting
that it is independent of AC7 and VIP regulation.
In vitro studies: macrophages
To provide some indication of which cells may be involved in VIP
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regulation of TLRs, peritoneal exudate macrophages and XS52 (Langerhans)
cells were tested in an in vitro assay. Compared with media control, ultrapure
LPS (only activates the TLR4 pathway) significantly increased TLR1 (Fig. 15A, p
< 0.001), TLR4 (Fig. 15B, p < 0.01), MyD88 (Fig. 15C, p < 0.001), IRAK1 (Fig.
15D, p < 0.01), and TRAF6 (Fig. 15E, p < 0.001) mRNA, with no effect on ST2
mRNA (Fig. 15G). However, SIGIRR mRNA (Fig. 15F, p < 0.001) was decreased
after LPS stimulation compared with media control stimulation. Compared with
LPS alone, LPS plus VIP significantly decreased mRNA levels of TLR1 (Fig. 15A,
p < 0.05), TLR4 (Fig. 15B, p < 0.01), MyD88 (Fig.15C, p < 0.001), IRAK1 (Fig.
15D, p < 0.001), and TRAF6 (Fig. 15E, p < 0.001) but increased ST2 (Fig. 15G, p
< 0.05); no difference was seen for SIGIRR (Fig. 15F). Cultured cells treated with
VIP alone showed no significant difference compared with media-treated controls
for any of the molecules tested.
In vitro studies: XS52 (Langerhans) cells
LPS versus media control treatment of XS52 (Langerhans) cells
significantly increased mRNA levels of TLR1 (Fig. 16A, p < 0.001), TLR4 (Fig.
16B, p < 0.001), MyD88 (Fig. 16C, p < 0.001), and TRAF6 (Fig. 16E, p < 0.001)
but decreased ST2 (Fig. 16G, p < 0.001). IRAK1 (Fig. 16D) and SIGIRR (Fig. 16F)
mRNA levels were unchanged after LPS stimulation compared with media control
stimulation. Compared with LPS alone, LPS plus VIP significantly decreased
mRNA levels of MyD88 (Fig. 16C, p < 0.05) and TRAF6 (Fig. 16E, p < 0.001) but
increased SIGIRR mRNA expression (Fig. 16F, p < 0.001). Compared with LPS
alone, LPS plus VIP did not significantly change mRNA levels of TLR1 (Fig. 16A),
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TLR4 (Fig. 16B), IRAK1 (Fig. 16D), or ST2 (Fig. 16G). Cultured cells treated with
VIP alone did not differ from media-treated controls for any of the molecules
tested.
Langerhans cell detection and quantitation
In normal, uninfected eyes, dendritic-shaped Langerhans cells were
detected in the peripheral cornea/conjunctiva of PBS-treated (Fig. 17A) and VIPtreated (Fig. 17B) mice; quantitatively, they were slightly decreased (not
significantly) after VIP treatment (Fig. 17G). At 1 d p.i., rounded, motile
Langerhans cells appeared to be decreased in the conjunctiva and peripheral
cornea of VIP-treated mice (Fig. 17D) compared with PBS-treated mice (Fig.
17C), and quantitation showed that the difference was significant (p < 0.05, Fig.
17G). By 3 d p.i., the cell number appeared similar in PBS-treated (Fig. 17E) and
VIP-treated (Fig. 17F) mice; when quantitated, no difference was seen between
the two groups (Fig. 17G).
3.5

Discussion
VIP regulates a wide variety of immune reactions; among its numerous

anti-inflammatory functions, it participates in the maintenance of immune
homeostasis (Gomariz et al., 2010; Smalley et al., 2009). Previously, our
laboratory showed that, in the cornea of B6 mice infected with P. aeruginosa, VIP
treatment regulates cytokine production through up-regulation of VIP receptor 1
on inflammatory cells, leading to less stromal destruction and prevention of
corneal perforation (Szliter et al., 2007). Recent work provided further evidence
that similar VIP treatment of B6 mice also has an indirect effect: it modulates
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growth factors, angiogenic molecules, and defensins in the infected cornea,
which, in turn, promote healing (Jiang et al., 2011). In addition, other studies
showed that VIP down-regulates pro-inflammatory TLRs and related molecules in
several nonocular disease models (Gomariz et al., 2007). TLRs, important in
innate immunity, are critical for recognition of conserved pathogen-associated
molecular patterns, through TLR/IL-1R expressed on the surface of various cell
types, to trigger cytokine/chemokine production (Chtarbanova and Imler, 2011;
Medzhitov and Janeway, 2000). In this regard, previous studies from this
laboratory and other investigators showed that TLR1 (Yuan and Wilhelmus,
2010), TLR3 (Johnson et al., 2008), TLR4 (Huang et al., 2006a), and TLR9
(Huang et al., 2005) play important roles in the pathogenesis of experimentally
induced keratitis. However, VIP regulation of TLRs during these diseases has not
been characterized. Thus, the current study, using a PCR array to profile 84 TLRrelated genes, provided an overview of the ability of VIP to provide master
regulation of TLRs and signaling-pathway molecules in bacterial keratitis.
Twenty-one genes were down-regulated ≥ 3-fold by VIP, and several of them
were selected for further confirmation by RT-PCR. The results indicated that VIP
reduced pro-inflammatory TLRs and related molecules (TLR1, TLR4, TLR6,
TLR8, TLR9, IRAK1, TRAF6, and Chuk), which agreed well with the array data.
The array did not contain two anti-inflammatory TLRs important in promoting the
resistance response of BALB/c mice to P. aeruginosa: SIGIRR (Huang et al.,
2006b) and ST2 (Huang et al., 2007); however, when tested by RT-PCR, these
genes, in general, were up-regulated by VIP treatment. Immunohistochemistry
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data further confirmed that VIP decreased TLR4 protein expression in both
epithelial and stromal layers of the cornea. These results also are consistent with
previous studies showing that VIP inhibits or even reverses TLR2 (Foster et al.,
2007), TLR3 (Lee et al., 2009), and TLR4 (Arranz et al., 2008a; Arranz et al.,
2008b) expression or their stimulated signaling pathways in other nonocular
disease models.
On ligand binding, TLRs recruit adaptor molecules, such as IRAK and
TRAF6, to their intracellular signaling domain, leading to the activation of several
kinases, as well as the transcription factor, NF-κB, thereby directly up-regulating
immune-response genes (Michelsen et al., 2004). In the current study, VIP
treatment in vivo down-regulated IRAK1 and TRAF6 mRNA levels, which is
consistent with other studies using synovial fibroblasts isolated from patients with
rheumatoid arthritis: compared with LPS alone, LPS stimulation plus VIP
treatment inhibited IRAK1 and TRAF6 mRNA and phosphorylated protein
expression (Arranz et al., 2008b), thereby acting as a negative regulator of TLR4
signaling.
Another important signaling complex, the IKK complex, is found
downstream of IRAK–TRAF6 signaling and is composed of IKKα, IKKβ, and IKKγ
(Israel, 2010). The current in vivo study showed that VIP inhibited Chuk/IKKα
mRNA expression, but only modestly decreased its activity, compatible with
previous in vitro studies showing that VIP directly inhibited IKKα activity in human
monocytes (Delgado and Ganea, 2001) and microglia cells (Delgado et al., 2008).
In microglial cells, VIP inhibition of IKKα reduced Aβ-induced neurodegeneration
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by indirectly inhibiting the production of numerous inflammatory and neurotoxic
molecules (Delgado et al., 2008). Furthermore, loss or decreased IKKα also was
suggested to negatively regulate NF-κB and subsequent gene expression by
inhibiting its translocation to the nucleus and, thus, down-regulating inflammation
(Anest et al., 2003).
In contrast to other TLRs, SIGIRR (Wald et al., 2003) and ST2 (Liew et al.,
2005), members of the TLR–IL-1R superfamily, act as negative regulators of IL-1
and LPS signaling. Previous studies from our laboratory found that SIGIRR
(Huang et al., 2006b) and ST2 (Huang et al., 2007) promote natural resistance of
BALB/c versus B6 mice against P. aeruginosa keratitis and that Ab depletion of
SIGIRR increased disease in BALB/c mice. However, it was not tested whether
VIP treatment regulates expression of either molecule in susceptible B6 mice.
The current study showed that in vivo treatment of infected B6 mice with VIP
increased (but not significantly) SIGIRR mRNA levels over PBS-treated controls
in normal uninfected eyes; at 1 d p.i., the levels decreased in both groups but
remained higher with VIP treatment. In previous work from our laboratory (Huang
et al., 2006b) comparing the expression of SIGIRR in BALB/c versus B6 mice
after P. aeruginosa infection, we also observed a decrease in mRNA expression
in both groups at 12 h p.i. (and in B6 mice at 1 d p.i., similar to the current study),
which increased in both mouse strains later in disease. SIGIRR protein levels
decreased in the two mouse strains at 1 d p.i. and increased later in disease,
most significantly in BALB/c mice (Huang et al., 2006b). After in vivo LPS
challenge, similar consumption of SIGIRR mRNA (protein not tested) was shown
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by Wald et al. (Wald et al., 2003); they suggested that this may reflect its
functional involvement in decreasing inflammation. We cited this possibility as
well but did not prove it functionally (Huang et al., 2006b). The current study
suggests that a decrease in SIGIRR protein is not required for functionality,
because we did not observe SIGIRR consumption at the protein level in B6 mice
treated with VIP; rather, protein levels were increased at 1 d p.i. These data are
supported by other studies in which overexpression of SIGIRR (adenoviral vector
expressing murine SIGIRR) was shown to ameliorate LPS-induced acute lung
injury in mice (Chen et al., 2011); its overexpression in human macrophages and
dendritic cells downregulated TLR-induced cytokines, whereas its knock down
increased cytokine production following TLR stimulation (Drexler et al., 2010). In
contrast, ST2 protein is increased later (7 d p.i.) in disease, suggesting that, after
VIP treatment, the molecules could act disparately in time to ameliorate disease
or participate in corneal healing.
Previous studies on the immunomodulatory properties of VIP led to the
identification of two pathways: one cAMP dependent and the other cAMP
independent (Chorny et al., 2006). However, whether VIP regulation of TLRs is
cAMP dependent or independent had not been tested. To address this issue, we
silenced AC7 using siRNA, because among the 10 adenyl cyclases it is highly
expressed in the immune system (Duan et al., 2010). Data showed that VIP
regulation of TLR1, TRAF6, and ST2 was cAMP dependent, because silencing
plus VIP treatment did not change the effects of silencing alone. These data
agree with previous, similarly designed in vitro studies in which a PKA inhibitor
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was used to block upstream cAMP pathways (Delgado et al., 1999b; Delgado et
al., 1999c). Data from those studies concluded that VIP regulation of both a
proinflammatory cytokine TNF-α (Delgado et al., 1999c) and NO (Delgado et al.,
1999b) are cAMP dependent. In contrast, the current study showed that
regulation of Chuk, IRAK1, IRAK2, TLR4, TLR9, and SIGIRR are cAMP
independent, because silencing plus VIP treatment changed the effects of
silencing AC7 alone. These data are consistent with in vitro studies showing that
VIP can function to regulate molecules, such as NF-κB, in a cAMP-independent
manner (Delgado and Ganea, 2001). Unexpectedly, compared with scrambled
control treatment, AC7 siRNA did not induce significant changes in TLR6;
however, when silencing was combined with VIP treatment, TLR6 levels were
decreased, suggesting the possibility that other adenyl cyclase isoforms (Song et
al., 2007) participate in TLR regulation by VIP.
Previous studies from our laboratory showed the importance of both
macrophages (McClellan et al., 2003) and Langerhans cells (Hazlett et al., 2002)
in Pseudomonas keratitis. In this regard, VIP functions as a macrophagedeactivating factor and was shown to down-regulate pro-inflammatory cytokine
expression (IL-1β and MIP-2) after LPS (not ultrapure) stimulation in murine
peritoneal macrophages (Szliter et al., 2007). It also down-regulates proinflammatory cytokine production in epidermal Langerhans cells (Kodali et al.,
2004), but its role in TLR regulation has not been characterized in these types of
cells. Data from the current study showed that, in peritoneal macrophages and
XS52 (Langerhans) cells, ultrapure LPS stimulation upregulated TLR1 and TLR4,
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but VIP plus LPS downregulated both TLRs only in macrophages. These data
agree with those of other investigators who showed that, compared with LPS
alone, stimulation of murine macrophages with LPS (not ultrapure) and VIP
resulted in less TLR4 expression at the transcriptional level (Arranz et al., 2008a);
however, no similar data are available for XS52 (Langerhans) cells or why they
respond dissimilarly to macrophages. With regard to TLR1, because other
investigators showed that cytokines, such as IFN-γ, can increase TLR1
expression in murine monocytes (Krutzik et al., 2003), we similarly tested for IFNγ after ultrapure LPS stimulation of both cell types and found elevated levels,
which also were decreased by treatment with LPS plus VIP (data not shown).
With similar treatment, TLR4 downstream-signaling molecules, including MD88,
IRAK1, and TRAF6, also were down-regulated in macrophages, whereas only
MyD88 and TRAF6 were down-regulated in XS52 (Langerhans) cells. The
current study also showed that, compared with LPS treatment alone, LPS
stimulation plus VIP increased ST2 mRNA expression in macrophages, but only
SIGIRR was increased in XS52 (Langerhans) cells. These data suggest that VIP
disparately regulates TLR on these cells and may reflect the kinetics of pathogen
encounter (ocular surface versus stroma) p.i. in the eye. Despite the differential
regulation of these cells, it is clear that VIP plus LPS reduces pro-inflammatory
TLR expression while promoting anti-inflammatory TLR expression. VIP
treatment in vivo also reduced Langerhans cell centripetal migration and, thus,
decreased the number of cells in the infected cornea at 1 d p.i. Other
investigators also showed that VIP treatment inhibits mouse dendritic cell
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migration to adjacent lymph nodes (Weng et al., 2007), limiting infection. All of
this is consistent with the anti-inflammatory effects of VIP and with previous
studies from our laboratory that showed that the presence of Langerhans cells in
the cornea (before infection) exacerbates subsequent disease (Hazlett et al.,
2002).
Overall, this study provides evidence that in vivo treatment with VIP downregulates pro-inflammatory TLRs and increases anti-inflammatory TLRs and
related signaling molecule expression via cAMP-dependent and -independent
pathways, as well as regulates Langerhans cell number and migration in the
infected cornea. In vitro studies using ultrapure LPS, which only activates the
TLR4 pathway, confirm the in vivo data and provide evidence that TLR
expression in macrophages and XS52 (Langerhans) cells is differentially
regulated by VIP to improve disease outcome.
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Table 2. Primer sequence of the Toll-like receptors and related molecule for
Real-Time PCR amplification
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Table 3. Selected TLRs from RT2 Profiler PCR array

- 75 -

- 76 -

FIGURE 11. RT-PCR for mRNA expression. Compared with PBS
treatment, VIP treatment decreased mRNA levels of TLR1 at 7 d p.i. (A), TLR4 at
1 d p.i. (B), TLR6 at 5 and 7 d p.i. (C), TLR8 at 7 d p.i. (D), TLR9 at 5 d p.i. (E),
IRAK1 at 1 and 5 d p.i. (F), TRAF6 at 5 and 7 d p.i. (H), and Chuk at 1 and 7 d p.i.
(I). VIP versus PBS treatment increased mRNA levels of SIGIRR at 5 and 7 d p.i.
(J) and for ST2 at 7 d p.i. (K). (G) No significant change was seen for IRAK 2, nor
were any changes seen at other times tested for any of the assays.
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FIGURE 12. ELISA. Compared with PBS treatment, VIP treatment had no
effect on total IKKα (A) in normal cornea (N) or infected cornea, but it significantly,
although slightly, decreased p-IKKα protein levels at 7 d p.i. (B), with no effect in
normal cornea (N) or at 1 d p.i. (C) ST2 protein levels were significantly
increased by VIP but only at 7 d p.i. (E) Western blot of SIGIRR protein levels in
the uninfected, normal cornea (N) and infected cornea (1 and 5 d p.i.) of PBS- or
VIP-treated mice. Equivalent protein was loaded (80 μg/lane) for all lanes except
lane 1. Lane 1, Murine rSIGIRR (15 ng); lane 2, PBS-treated normal cornea (N);
lane 3, PBS-treated cornea at 1 d p.i.; lane 4, PBS-treated cornea at 5 d p.i.; lane
5, VIP-treated normal cornea (N); lane 6, VIP-treated cornea at 1 d p.i.; lane 7,
VIP-treated cornea at 5 d p.i. (D) The intensity of bands was quantitated and
normalized to the β-actin control. Data (mean ± SEM integrated density values at
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each time point) are significant only at 1 d p.i.
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FIGURE 13. TLR4 immunostaining. At 1 and 5 d p.i., TLR4 staining (red)
was less intense in the epithelium and stroma after VIP (B, D) treatment
compared with PBS (A, C) treatment. PBS-treated (E) and VIP-treated (F)
controls (1 d p.i.), in which the primary Ab was replaced by IgG, were negative for
TLR4 immunostaining. Original magnification ×100.
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FIGURE 14. (A) When tested at 5 d p.i., RT-PCR confirmed that,
compared with scrambled control treatment, silencing AC7 significantly
decreased AC7 mRNA levels; silencing plus VIP treatment did not reverse the
effect. When tested at 5 d p.i., silencing AC7 increased mRNA levels of TLR1 (B),
whereas TRAF6 (C) and ST2 (D) were decreased. Silencing plus VIP injection
did not change the effect of silencing for any of the above-mentioned molecules.
In contrast, compared with scrambled control treatment, Chuk (E), IRAK1 (F),
TLR4 (G), TLR9 (H), and IRAK2 (I) mRNA levels were increased after silencing
AC7. Silencing plus VIP injection decreased mRNA expression of each of these
molecules significantly. (J) SIGIRR mRNA levels were decreased after silencing
AC7; however, silencing plus VIP treatment resulted in increased mRNA levels
over silencing alone. No significant changes in mRNA levels of TLR6 (K) or TLR8
(L) were seen with AC7 siRNA treatment; however, silencing plus VIP treatment
resulted in reduced mRNA levels of TLR6.
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FIGURE

15.In vitro studies using macrophages. Compared with

stimulation of macrophages with media control, ultrapure LPS significantly
increased mRNA levels of TLR1 (A), TLR4 (B), MyD88 (C), IRAK1 (D), and
TRAF6 (E), whereas it decreased mRNA levels of SIGIRR (F) and had no effect
on ST2 (G). Compared with LPS alone, LPS plus VIP treatment significantly
decreased mRNA expression of TLR1 (A), TLR4 (B), MyD88 (C), IRAK1 (D), and
TRAF6 (E), whereas it increased ST2 (G) and had no effect on SIGIRR (F).
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Compared with media control, VIP alone had no significant effect on any of the
molecules tested.
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FIGURE 16. In vitro studies using XS52 (Langerhans) cells. Compared
with media control, stimulation of these cells with ultrapure LPS significantly
increased mRNA levels of TLR1 (A), TLR4 (B), MyD88 (C), and TRAF6 (E),
whereas it decreased mRNA levels of ST2 (G) and had no effect on IRAK1 (D) or
SIGIRR (F). Compared with LPS alone, VIP plus LPS treatment significantly
decreased MyD88 (C) and TRAF6 (E), increased SIGIRR (F), and had no
significant effect on TLR1 (A), TLR4 (B), IRAK1 (D), or ST2 (G). Cultured cells
treated with VIP alone did not differ from media-treated controls for any of the
molecules tested.
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FIGURE 17. Staining and quantitation of Langerhans cells. In the normal,
uninfected eye (conjunctiva/peripheral cornea), dendritic-shaped ADPase+
Langerhans cells appeared similar in number after VIP (B) or PBS (A) treatment.
At 1 d p.i., rounded ADPase+ cells in the peripheral cornea appeared to be
decreased in number after VIP treatment (D) compared with PBS treatment (C).
At 3 d p.i., cells appeared qualitatively similar after PBS (E) or VIP (F) treatment.
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Insets show examples of cells. (G) Quantitation confirmed these findings. (A–F)
Original magnification ×375; field size, 270 μm2.
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Chapter 4
THE ROLE OF VIP IN CORNEA
4.1

Abstract
Purpose: Exogenous VIP down-regulates pro- but upregulates anti-

inflammatory cytokines, growth factors (GFs) and TLRs promoting healing in
experimental P. aeruginosa keratitis. Whether VIP is required for GF or GF
receptor (R) expression in normal and infected cornea is unknown and the
purpose of this study. Methods: VIP knockout (-/-) and wild type (WT) C57BL/6
(B6) mice were infected and tested using PCR array, real-time RT-PCR, ELISA
and immunostaining. VIP antagonist treatment studies also were done using B6
and BALB/c mice. Results: Infected corneas of VIP-/- vs WT B6 mice perforated
earlier [2 vs 5 days postinfection (p.i.)] and array data showed that GFs were
differentially changed between groups. RT-PCR revealed that the infected cornea
of VIP-/- vs WT mice expressed higher mRNA levels of EGF and HGF, reduced
FGF, EGFR and HGFR, with no difference in FGFR; differences between groups
were not seen in normal cornea. Immunostaining for GF and GFR in the normal
cornea of VIP-/- vs WT mice were similar for both. However, at 1 day p.i., VIP-/- vs
WT mice had more intense EGF and HGF, similar FGFR, and reduced FGF,
EGFR, and HGFR staining. VIP antagonist treatment decreased protein levels for
GFR at 5 days p.i. in both B6 and BALB/c mice, with no significant changes in
normal cornea. Conclusions: The data show that endogenous VIP is not requisite
for GF or GFR expression in the normal cornea, but after infection, its absence or
reduction is critical for their regulation.
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4.2

Introduction
P. aeruginosa, an opportunistic, Gram negative pathogen, is one of the

most virulent organisms associated with microbial keratitis and is often
associated with contact lens use (Wilhelmus, 1987). Infections progress rapidly
and lead to inflammatory epithelial edema, stromal infiltration, corneal ulceration,
and oftentimes vision loss (Hazlett, 2004). Experimental murine models of the
disease have been established: Th1 responder mouse strains (e.g., C57BL/6, B6)
are susceptible (cornea perforates), whereas Th2 responder strains (e.g., BALB/c)
are resistant (cornea heals) (Hazlett et al., 2000).
In previous studies using these murine models, we provided evidence that
an anti-inflammatory neuropeptide, VIP promotes resistance against P.
aeruginosa corneal infection by regulation of cytokine production and subsequent
alteration of the host inflammatory cell response (Szliter et al., 2007). In addition,
recent studies from this laboratory have provided mechanistic information that
VIP treatment modulates keratitis through regulation of growth factors,
angiogenic molecules, beta defensins (Jiang et al., 2011) and Toll-like receptors
(TLR) (Jiang el al., 2012) in the infected cornea, contributing to healing. However,
whether endogenous VIP is required for production of growth factors (GF) or
growth factor receptors (GFR) in the normal, uninfected cornea and after
infection remains untested. This is of importance to determine, since it has been
demonstrated in other experimental models (Ware and Matthay, 2002;
Woodworth et al., 2005) that one of the ways that inflammation can be regulated
is through growth factor binding to their receptors. Thus, the current study
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investigated the expression of growth factors and their receptors in the normal
and infected cornea of VIP knockout (VIP-/-) vs wild-type (WT) mice. Data from
the studies provide evidence that the normal cornea of both groups of mice is
similar morphologically and have a similar pattern of GF and GFR expression,
suggesting that endogenous VIP is not requisite for their expression. However,
after infection, corneal perforation occurred more rapidly (2 days p.i.) in knockout
vs WT mice and real time RT-PCR and immunostaining studies showed
disparate expression of GF and their receptors in the two groups. As the GFR
appeared to be most consistently affected, B6 and BALB/c mice were treated
with a VIP antagonist, infected and tested for GFR expression. In this experiment,
GFR proteins were reduced for both murine strains, confirming the trend in the
knockout data. Overall, the current study provides evidence that endogenous VIP
is not required for normal corneal expression of GF or GFR. However, if it is
absent or reduced, GFs and their receptors are disregulated and the infected
cornea perforates rapidly.
4.3

Materials and Methods
Infection
-/-

Eight-week-old female C57BL/6, VIP (B6.129S4-Viptm1Clw/J) and BALB/c
mice, purchased from The Jackson Laboratory (Bar Harbor, ME), were
anesthetized with ethyl ether and placed beneath a stereoscopic microscope at
x40 magnification. The cornea of the left eye was wounded (Rudner et al., 2000)
and a 5-µl aliquot containing 1.0 x 106 CFU of P. aeruginosa (American Type
Culture Collection, strain 19660, Manassas, VA) was topically delivered. Animals
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were treated humanely and in compliance with the Association for Research in
Vision and Ophthalmology Statement on the Use of Animals in Ophthalmic and
Vision Research.
Ocular response to bacterial infection
Corneal disease was graded: (Hazlett et al., 1987) 0 = clear or slight
opacity, partially or fully covering the pupil; +1 = slight opacity, fully covering the
anterior segment; +2 = dense opacity, partially or fully covering the pupil; +3 =
dense opacity, covering the entire anterior segment; and +4 = corneal perforation
or phthisis. After infection, a clinical score was recorded (days 1 and 2) for each
group of mice (n = 5/group/treatment).
VIP antagonist treatment
BALB/c

and

B6

mice

(n

=

5/group/time/assay)

were

injected

intraperitoneally with 100 μL PBS containing 10 μg VIP antagonist (McClellan et
al., 2008) (Bachem, San Carlos, CA) on days −1, 0 (day of infection), and daily
through 5 days p.i. Control mice were similarly injected with PBS. Normal,
uninfected and infected corneas were collected at 3 and 5 days p.i. for real-time
RT-PCR mRNA detection and 5 days p.i. for ELISA assay.
Real-time RT-PCR
Total RNA was isolated from an individual cornea using RNA-Stat 60
(Invitrogen, Carlsbad, CA), per the manufacturer’s recommendations and
quantitated spectrophotometrically (260 nm). One microgram of total RNA was
reverse transcribed using MMLV reverse transcriptase. The 20 µl reaction
mixture containing 200 U of MMLV-reverse transcriptase, 10 U of RNase Inhibitor,
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500 ng of oligo (dT) primers, 10 mM dNTP, 100 mM DTT, and MMLV reaction
buffer (Invitrogen, Carlsbad, CA). After, cDNA was amplified using SYBR Green
Master Mix (Bio-Rad), per the manufacture’s recommendation. Briefly, the 20 µl
reaction system contained: 10 µl of SYBR Green PCR Master Mix, 0.5 µM
primers, 2 µl of cDNA (diluted 1/25), and diethyl pyrocarbonate water. All primer
sets for the PCR array were purchased as a 96-well plate (RT2 Profiler Mouse
Wound Healing PCR Array; SABiosciences Corporation, Frederick, MD). The
individual primer sets were designed using PrimerQuest (Integrated DNA
Technologies, Cambridge, MA). Sequences of primers for

β-actin, EGF, EGFR,

FGF, FGFR, HGF and HGFR are shown (Table 4).
Quantitative real-time RT-PCR was performed using the MyiQ single color
real-time RT-PCR detection system (Bio-Rad). Optimal conditions for PCR
amplification of cDNA were established using routine methods (Heid et al., 1996).
Relative mRNA levels were calculated after normalization to β-actin.
Immunofluorescent staining
Normal, uninfected and infected eyes were enucleated (n = 3/group/time)
at 1 day p.i. from WT and VIP-/- mice, immersed in 1X Dulbecco’s PBS
(Mediatech, Inc., Herndon, VA), embedded in Tissue-Tek OCT compound (Miles,
Elkhart, IN), and frozen in liquid nitrogen. Ten-micrometer sections were cut,
mounted to polylysine-coated glass slides, and stored at 37°C overnight. After a
2 min fixation in acetone, slides were blocked with 10 mM sodium phosphate
buffer containing 2.5% BSA and donkey IgG (1/100) for 30 min at room
temperature. Then, sections were incubated for 1 h with goat anti-mouse EGF
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(15 µg/ml; R&D Systems, Minneapolis, MN) or goat anti-mouse HGF (15 µg/ml;
R&D Systems) antibody. Antibodies for EGF and HGF were incubated
simultaneously with antibodies for their receptors, goat anti-mouse EGFR (15
µg/ml; R&D Systems) or goat anti-mouse HGFR (15 µg/ml; R&D Systems). This
was followed by secondary antibodies, Alexa Fluor 594-conjugated donkey antigoat antibody (for EGF and HGF, respectively, 1/1500; Invitrogen), and Alexa
Fluor 633-conjugated donkey anti-goat antibody (for EGFR and HGFR,
respectively, 1/1500; Invitrogen) for another hour.
Staining for FGF and its receptor, FGFR was done sequentially. After
incubating the sections with goat anti-mouse FGF antibody (1/100, Santa Cruz
Biotechnology) for 1 h followed by the secondary Alexa Fluor 633-conjugated
donkey anti-goat (1/2000; Invitrogen) for another hour, sections were incubated
with rabbit anti-mouse FGFR AB (1/100, Santa Cruz), 1 h, and Alexa Fluor 546conjugated donkey anti-rabbit secondary (1/1500; Invitrogen) for another hour.
Controls were similarly treated, but the primary Abs were replaced with the same
host

IgG,

ChromPure

goat

or

rabbit

IgG

(Jackson

ImmunoResearch

Laboratories). Finally, sections were visualized and digital images captured with a
Leica TCS SP2 confocal laser scanning microscope (Leica Microsystems).
ELISA
Protein levels for GFR were tested using ELISA kits. Corneas from PBS
and VIP antagonist treated mice were individually collected (n = 5/group/time)
from normal uninfected and infected corneas at 5 days p.i. For EGFR (EIAab
Science Co. Ltd, Wuhan, China), for HGFR (R&D Systems) and for FGFR
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(MyBioSource, San Diego, CA), corneas were homogenized in 0.5 ml of PBS
with 0.1% Tween 20 and protease inhibitor (1 tablet/10 ml, Roche). All samples
were centrifuged at 13,000 rpm for 5 min and an aliquot of each supernatant was
assayed in duplicate per the manufacturer’s instructions. Sensitivities of the
ELISA assays were <0.08 ng/ml for EGFR, <10.0

g/ml for HGFR, and <0.1

ng/ml for FGFR.
Statistics
The difference in clinical score between two groups was tested by the
Mann-Whitney U test. For all other experiments, an unpaired, two-tailed Student’s
t test (for comparisons between two groups) was used. P<0.05 was considered
to be statistically significant.
4.4

Results
Ocular response in VIP-/- mice
VIP-/- vs WT mice showed similar disease scores at 1 day after infection.

At 2 days p.i., a significantly higher mean clinical score (Fig. 18, p<0.05),
indicative of worsened disease and/or perforation was recorded for the knockout
mice. Typical responses for each of the two groups was documented by
photography using a slit lamp and showed that WT (B) mice had opacity over the
anterior segment, while VIP-/- (C) mice exhibited corneal perforation, with the
remainder of the eye heavily opaque due to the presence of an inflammatory
infiltrate.
PCR array and real-time RT-PCR
To determine whether endogenous VIP is required for GF production,
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mRNA levels of 84 Wound Healing related genes were profiled by PCR array at 1
day p.i. (Table 5). Eighteen of these GF and related molecules (e.g., EGF, EGFR,
FGF, and HGF) were differentially changed in VIP-/- vs WT B6 mice and are listed
in Table 5. RT-PCR was used to selectively confirm the array data and to test for
FGFR and HGFR which are receptors for FGF and HGF but not included on the
array. In the normal, uninfected cornea, we found no significant difference at the
mRNA level between the two mouse groups for GF or GFR expression (Fig. 19
A-F). However, at 2 days p.i., VIP-/- vs WT mice showed significantly increased
mRNA levels for EGF (Fig. 19A, p<0.01) and HGF (Fig. 19E, p=0.01) but lower
levels of FGF (Fig. 19C, p<0.01). For GFR, EGFR (Fig. 19B, p<0.01) and HGFR
(Fig. 19F, p<0.01) were significantly decreased in VIP-/- vs WT mice, with no
significant changes to FGFR (Fig. 19D).
Immunostaining
Immunostaining confirmed the mRNA data above and showed no
differences between the two groups of mice in the normal cornea for either the
GFs (Fig. 20) or for the GFRs (Fig. 21). When comparing the two groups at 1 day
p.i. (Fig. 22), immunostaining of the cornea of VIP-/- vs WT mice revealed
increased EGF and HGF, while FGF staining was decreased. For the GFRs,
comparison in immunostaining between the two groups at 1 day p.i. (Fig. 23)
revealed that VIP-/- mice had decreased EGFR and HGFR staining, while staining
for FGFR was similar. All controls (Figs. 20-23) in which the primary antibody was
replaced with same species IgG, were negative for immuunostaining.
Real-time RT-PCR
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Next, to further test the effects of VIP on GF and GFR expression, realtime RT-PCR was done using B6 mice treated with a VIP antagonist vs PBS.
Similar to the VIP-/- experiments, there was no significant difference between the
two groups of mice at the mRNA level in either GFs or GFRs in the normal,
uninfected cornea (Fig. 24 A-F). However, at 5 days p.i., VIP antagonist vs PBS
treated mice showed significantly increased mRNA levels for EGF (Fig. 24A,
p=0.01) and HGF (Fig. 24E, p<0.01), with decreased levels for FGF (Fig. 24C,
p=0.05). For GFRs, EGFR (Fig. 24B, p=0.01) and HGFR (Fig. 24F, p=0.05) were
significantly decreased in VIP antagonist vs PBS treated mice, while there was
no significant change for FGFR (Fig. 24D).
ELISA
GFRs were tested at 5 days p.i. in B6 (Fig. 25 A,C,E) and BALB/c (Fig. 25
B,D,F) mice after treatment with VIP antagonist. For B6 mice, treatment with the
VIP antagonist resulted in reduced levels of EGFR (A), although not significant,
while reduction in both FGFR (C, p=0.01) and HGFR (E, p<0.01) were significant.
For BALB/c mice, VIP antagonist treatment significantly reduced all three GFR,
EGFR (B, p<0.001), FGFR (D, p<0.01) and HGFR (F, p<0.01). No difference in
GFRs between groups was detected in normal cornea.
4.5

Discussion
The neuropeptide VIP is a multifunctional molecule and regulates immune

reactions and also participates in the maintenance and restoration of immune
homeostasis (Souza-Moreira et al., 2011). In addition, VIP has been considered
in itself to be a growth factor (Gressens et al., 1997), as well as a type 2 cytokine
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(Pozo and Delgado, 2004).
In prior work, our laboratory has provided evidence that treatment with
synthetic VIP regulates expression of pro- and anti-inflammatory cytokines
(Szliter et al., 2007), growth factors (Jiang et al., 2011), and Toll-like receptors
(Jiang et al., 2012) in P. aeruginosa induced keratitis. This leads to decreased
stromal destruction in a B6 mouse model in which the untreated, infected cornea
perforates within 5-7 days after experimental infection (Szliter et al., 2007). The
present study, using VIP-/- mice tested whether the endogenous absence of VIP
or its reduction using an inhibitor, contributed to modulation of growth factors and
their receptors. No detectable differences in either GFs or GFRs were detected in
the normal cornea by either RT-PCR or by immunostaining. Neither was there
detectable differences in corneal morphology between the two groups. In contrast,
in other models, the absence of VIP has been shown to lead to overall altered
intestinal morphology, as well as thickening of smooth muscle and increased villi
length in the bowel (Lelievre et al., 2007). In whole cultured embryonic 9.5 mouse
embryos, VIP regulated insulin growth factor-I and embryonic development and
when pregnant mice were treated with a VIP antagonist, inhibition of embryonic
growth occurred (Servoss et al., 2001).
After infection, in the absence of the neuropeptide, GFs and GFRs were
dysregluated when tested by PCR array, RT-PCR and immunostaining and the
cornea perforated more rapidly (within 2 days after infection) for the majority of
the knockout vs WT mice. Furthermore, either the endogenous absence of VIP or
antagonist treatment of B6 mice led to this dysregulation. Specifically, VIP
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antagonist treatment of B6 mice reduced all three GFRs at the mRNA level (all
significantly except for FGFR). And when either B6 or BALB/c mice were treated
with a VIP antagonist, GFR protein levels were decreased in both strains of mice
when compared with controls. In this regard, others have shown interaction of
VIP with the EGFR previously. In vitro studies have shown that Gq proteincoupled receptor agonists such as VIP can directly activate (phosphorylate) the
EGFR in T84 colonic epithelial cells by signaling pathways involving cAMP and
protein kinase A and regulate Cl- secretion (Bertelsen et al., 2004). In another
study, it was reported that during infection of human alveolar epithelial cells with
Pseudomonas fluorescens, a gram-negative rod, blocking EGFR increased
epithelial susceptibility to pathogen induced epithelial cell death (Choi et al.,
2011), consistent with, although not tested in our keratitis model. Another growth
factor, KGF/FGF-7 (FGF) and its receptor (FGFR), were both found to reduce
Pseudomonas infection in a lung model, through reducing bacterial load, since
intratracheal FGF was found to increase clearance of P. aeruginosa (Viget et al.,
2000). Another study using an experimental burn model in human keratinocytes,
also found that when FGF was added to P. aeruginosa in the presence of
keratinocytes, bacterial growth was inhibited and the same was observed when
genetically modified keratinocytes were used (Sobral et al., 2007). In addition, P.
aeruginosa infection in a bioengineered skin model, in which FGF7 was
expressed in diploid human keratinocytes, led to increased antimicrobial βdefensin-2 and cathelicidin (LL-37) production and reduced bacterial load when
compared with controls (Erdag et al., 2004). Previous studies from our laboratory
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also found that treatment using a GF mixture, composed of EGF, FGF and HGF,
increased murine beta-defensin-2 (mBD-2) and mBD3 expression, as well as
decreasing bacterial plate counts, resulting in less disease severity in the
infected cornea (Jiang et al., 2011). FGF also has been shown to promote wound
healing in skin epithelium (Marchese et al., 1995) and participates in lung
epithelial repair as well (Ware and Matthay, 2002). Since many cases of bacterial
keratitis result either directly or indirectly from disruption of the corneal epithelium
(O'Brien, 2003), it also is possible that earlier perforation observed in VIP-/- mice
may be due to reduced FGF levels with subsequent epithelial defect. HGFR
mRNA and protein (immunostaining) are also decreased in the VIP-/- mice. HGFR
recognizes HGF which has anti-inflammatory properties, in that it can target
vascular endothelial cells and disrupt nuclear factor-kappa B (NF-κB) signaling in
these cells (Gong et al., 2006),critical to regulating inflammatory cytokines.
Overall, this study provides evidence that although VIP is not required for
GF and GFR expression in normal cornea, either its absence or reduction results
in dysregualted GF and GFR expression in the cornea and enhanced disease.
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Table 4. Primer sequence of the growth factors and their receptors primers for
Real-Time PCR amplification.
Gene
β-actin
EGF
EFGR
FGF
FGFR
HGF
HGFR

Primer Sequence (5’ - 3’)
F – GAT TAC TGC TCT GGC TCC TAG C
R – GAC TCA TCG TAC TCC TGC TTG C
F – ACG GTT TGC CTC TTT TCC TT
R – GTT CCA AGC GTT CCT GAG AG
F – GTG GAG GGA CAT CGT CCA AA
R – ATT GGG ACA GCT TGG ATC ACA T
F – AAC AGC TAC AAC ATC ATG GAA ATC AG
R – AAT CAG TTC TTT GAA GTT GCA ATC CT
F – GTG CTT ATT GGG GAG TAT CTC CA
R – GAT CCA AGT TTC ACT GTC TAC CG
F – ACT TCT GCC GGT CCT GTT G
R – GGG ATG GCG ACA TGA AGC A
F – GTG AAC ATG AAG TAT CAG CTC CC
R – TGT AGT TTG TGG CTC CGA GAT

Size (bp)
147
130
100
153
102
66
100
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Table 5. Selected GFs from The Mouse Wound Healing RT2 ProfilerTM PCR array

Genes

Fold
Differences
VIP-/- / WT

Angpt1

-6.45

Csf2

-1.79

Csf3

1.03

Ctgf

-2.06

Egf

1.47

Egfr

-1.83

Fgf10

4.69

Fgf2

-1.41

Fgf7

-5.03

Hbegf

-2.11

Hgf

1.25

Igf1

-3.63

Mif

1.21

Pdgfa

1.16

Tgfa

-2.03

Tgfb1

1.45

Tnf

1.92

Vegfa

1.27
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Figure 18. VIP-/- and WT B6 mice. Clinical scores (A) indicated statistically
significant differences at 2 days p.i. between groups. Photographs taken with a
slit lamp at 2 days p.i. showed an early perforation in VIP-/- (C) vs WT (B) mice.
Magnification = ×7.
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Figure 19. GF and GFR mRNA expression. At 2 days p.i., EGF (A) and HGF (E)
were significantly increased, while FGF (C) mRNA levels were significantly
decreased in VIP-/- vs WT mice. EGFR (B) and HGFR (F) were decreased
significantly, while FGFR (D) mRNA was similar in the two groups. No significant
changes between the two groups were seen in normal cornea.
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Figure 20. GF immunostaining in normal cornea. GF staining was similar in VIP-/and WT B6 mice. Negative controls, in which the primary antibody was replaced
with a species-specific IgG, showed no positive staining. Magnification = 170X
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Figure 21. GFR immunostaining in normal cornea. GFR staining did not
difference between VIP-/- and WT B6 mice. Negative controls, in which the
primary antibody was replaced with a species-specific IgG, showed no positive
staining. Magnification = 170X
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Figure 22. GF immunostaining at 1 day p.i. Greater staining intensity for EGF
and HGF, with reduced intensity for FGF was seen in VIP-/- compared to WT B6
mice. Negative controls, in which the primary antibody was replaced with a
species-specific IgG, showed no positive staining. Magnification = 170X.
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Figure 23. GFR immunostaining at 1 day p.i. Staining for GFRs was less intense
for EGFR and HGFR in VIP-/- compared to WT B6 mice. No difference for FGFR
was noted between groups. Negative controls, in which the primary antibody was
replaced with a species-specific IgG, showed no positive staining. Magnification =
170X.
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Figure 24. GF and GFR mRNA expression. EGF (A) and HGF (E) were
significantly increased, while FGF (C) was decreased in VIP antagonist treated
B6 mice at 5 days p.i. EGFR (B) and HGFR (F) were significantly decreased with
no difference in FGFR (D) after VIP antagonist treatment. No difference was
detected between groups in normal, uninfected cornea.
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Figure 25. GFR ELISA analysis. VIP antagonist vs PBS treatment decreased
GFR (A-F) in both B6 and BALB/c mice at 5 days p.i. All were significant except
for EGFR (A). No significant changes were seen in the normal cornea between
two groups.
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Chapter 5
CONCLUSIONS
Host immunity has been considered as an important factor in determining
the prognosis of microbial keratitis (Hazlett LD et al., 2004). Previous study has
found that VIP promoted resistance against P. aeruginosa induced corneal
infection by regulating cytokine production and subsequently altering the host
inflammatory response (Szliter et al., 2007). However, the role of VIP in
regulation of growth factors and TLRs during P. aeruginosa keratitis remained
untested. In this regard, current studies provide important insights showing that
VIP modulates growth factors and TLR signaling in the infected cornea and these
in turn, contribute to better disease outcome.
In chapter 2 (This part of the work has been published: Jiang et al., 2011),
we found that VIP vs PBS treatment increased growth factor and angiogenic
molecules mRNA and protein levels in infected B6 mouse cornea. In order to
assess whether the anti-inflammatory effect of VIP was through regulating growth
factors, a mixture of EGF, FGF and HGF was topically applied after infection.
Treatment with a mixture of growth factors prevents corneal perforation, downregulated

pro-inflammatory

cytokines

but

up-regulated

anti-inflammatory

cytokines and β defensins, as well as delaying bacterial growth, indicating the
anti-inflammatory effects of VIP are partially achieved through regulating growth
factor production.
In chapter 3 (This part of work has been published: Jiang et al., 2012), our
work provided evidence that VIP vs PBS treatment decreased pro-inflammatory
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TLRs but increased anti-inflammatory TLRs in infected B6 mouse cornea and
also in XS52 (Langerhans) cells and peritoneal macrophages. To determine
whether VIP effects were cAMP dependent, mice were injected with AC7 siRNA
with or without VIP treatment and tested for TLR and related molecules mRNA
expression. The results indicated that VIP regulates TLR1, TRAF6 and ST2 in a
cAMP dependent manner, but Chuk, IRAK1, 2, TLR4, 9 and SIGIRR were found
to be cAMP independent. Moreover, we found that exogenous VIP treatment,
compared to PBS control, reduced Langerhans cell number in early (1 day p.i.)
infected cornea.
In chapter 4 (This part of work has been submitted for publication and is in
revision, 2012), we investigated whether VIP is required for expression of growth
factors and their receptors in normal and infected cornea. Our data provide solid
evidence of the importance of VIP in host resistance against corneal P.
aeruginosa infection. We observed that VIP-/- vs WT B6 mouse corneas showed
more severe infection and earlier perforation. PCR array and real time RT-PCR
data indicated that growth factors and their receptors were differentially changed
in infected VIP-/- vs WT mouse cornea; differences between groups were not
seen in normal cornea. Immunostaining for growth factors and their receptors in
normal and infected cornea of both groups of mice showed similar results when
compared with the mRNA data. Additionally, VIP antagonist treatment decreased
protein levels for growth factor receptors at 5 days p.i. in both B6 and BALB/c
mice, with no significant changes in normal cornea. These results indicate that
endogenous VIP is not required for the expression of growth factors and their
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receptors in normal cornea, but critical for their regulation after infection.
In summary, this dissertation has focused upon how VIP regulates host
immunity to promote resistance against corneal infection. Our data suggest that
VIP modulates growth factors and their receptors as well as TLR expression,
contributing to corneal healing. The findings presented herein provide further
evidence to justify testing VIP clinically either alone, or with antibiotics, to treat
microbial keratitis.
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The purpose of the current dissertation was to examine how VIP regulates
host immunity and corneal healing, specifically, its control of growth factors and
TLR expression in the P. aeruginosa infected cornea. Firstly, VIP treatment
increased growth factor expression (EGF, HGF, FGF and VEGF) in infected
cornea. Notably, treatment with a mixture of EGF, FGF and HGF prevented
corneal perforation, reduced pro-inflammatory cytokines and bacterial plate count,
while increasing anti-inflammatory cytokines and antimicrobials such as murine
β-defensin2 and 3.
We also investigated the expression of TLR-signaling pathways in P.
aeruginosa-infected corneas with or without VIP treatment. PCR array and realtime RT-PCR data demonstrated that VIP treatment decreased pro-inflammatory,
but increased anti-inflammatory TLRs. Immunohistochemistry, ELISA and
western blot results further confirmed the PCR data. AC7 siRNA experiments
indicated that VIP regulated TLR1, TRAF6 and ST2 in a cAMP dependent
manner, but Chuk, IRAK1, 2, TLR4, 9 and SIGIRR were cAMP independent. In
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vitro, VIP down-regulated pro-inflammatory, but increased anti-inflamamtory
TLRs in macrophages and Langerhans (XS52) cells. Exogenous VIP also
decreased Langerhans cell number in the infected cornea.
Furthermore, we used VIP-/- mice to asses whether VIP is required for
expression of growth factors and their receptors in normal and infected cornea.
VIP-/- vs WT B6 mice showed earlier corneal perforation. PCR array showed
growth factors are differentially changed between groups. Real time RT-PCR and
immunostaining studies revealed that the infected cornea of VIP-/- vs WT mice
expressed higher EGF and HGF, reduced FGF, EGFR and HGFR and similar
FGFR; no significant difference between the two groups of mice were seen in
normal cornea. VIP antagonist treatment decreased protein levels for growth
factor receptors at 5 days p.i. in both B6 and BALB/c mice, with no significant
changes in normal cornea.
In summary, these data provide evidence that VIP modulate growth factors,
angiogenic molecules and beta defensins in the infected cornea; that it reduced
pro-inflammatory, but increased anti-inflammatory TLRs after corneal infection;
and that it is not required for growth factor production in the normal cornea but
required in the infected cornea to delay perforation.
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